Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC

19187

Studies in scope

all four open statuses

11790

Recruiting now

open to new participants

2028

Lead sponsors

across recruiting studies

Top sites

Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343

Trials with a site in Guangzhou

Status

Study

Lead sponsor

Phase

Enrol

Chinese sites

Start

Active, closed

Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps

NCT07107256Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

DrugTQC2731

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Phase 3

246

Fuyang, Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen

2025-09-25

Recruiting

PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

NCT07188610CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 2

100

Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou

2025-09-25

Recruiting

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT07123454B-cell Non-Hodgkin Lymphoma

DrugSurovatamig

AstraZeneca

Phase 1/2

164

Chengdu, Guangzhou

2025-09-24

Recruiting

A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

NCT07141706Advanced/Metastatic Solid Tumors

DualityBio Inc.

Phase 1

253

Guangzhou, Harbin, Zhengzhou, Jinan

2025-09-23

Recruiting

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

NCT07164170Non-Small Cell Lung Cancer

DrugsABSK043·Glecirasib

Abbisko Therapeutics Co, Ltd

Phase 2

Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan

2025-09-22

Recruiting

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

NCT07053423Chronic Obstructive Pulmonary Disease

DrugDupilumab

Sanofi

Phase 4

218

Chengdu, Guangzhou, Hangzhou, Harbin, Ningbo, Xiamen

2025-09-22

Recruiting

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07111520Non-small Cell Lung Cancer

DrugsBNT326·Pumitamig

BioNTech SE

Phase 1/2

880

Baoding, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei

2025-09-22

Recruiting

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

NCT07154264Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

DrugsBirelentinib·Venetoclax

Dizal Pharmaceuticals

Phase 2

Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Yichang, Changsha, Changzhou

2025-09-22

Not yet open

A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

NCT07198321Cancer, PDAC, CRC (Colorectal Cancer), NSCLC

DrugGFH276

Genfleet Therapeutics (Shanghai) Inc.

Phase 1/2

450

Guangzhou

2025-09-22

Recruiting

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967Plaque Psoriasis

DrugsUstekinumab·Deucravacitinib

Bristol-Myers Squibb

Phase 3

3,040

Bengbu, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin

2025-09-22

Not yet open

Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base

NCT07145931Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy, Objective Response Rate

DrugCisplatin

Sun Yat-sen University

Phase 2

Guangzhou

2025-09-20

Active, closed

Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer

NCT07180212Bladder Cancer, Liquid Biopsy, Cystoscopy

Tianjin Medical University Second Hospital

Not applicable

360

Xingtai, Guangzhou, Haerbin, Kunming, Nanchang, Tianjin

2025-09-20

Recruiting

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

NCT07157787Primary Membranous Nephropathy

Alexion Pharmaceuticals, Inc.

Phase 2

Baotou, Beijing, Guangzhou, Shenzhen

2025-09-19

Active, closed

AI-Driven Accurate Diagnosis of Pathogens in Severe Pneumonia

NCT07461714Severe Pneumonia

Guangzhou Medical University

Observational

1,000

Guangzhou

2025-09-18

Active, closed

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07169578Alzheimers Disease

DrugTrontinemab

Hoffmann-La Roche

Phase 3

1,101

Xuzhou, Shanghai, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou

2025-09-17

Recruiting

Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab

NCT07192185Hepatocellular Carcinoma (HCC)

DrugsAtezolizumab & Bevacizumab·Folfox

Sun Yat-sen University

Phase 2

Guangzhou

2025-09-17

Recruiting

JS207 Combination Therapy in Triple-negative Breast Cancer

NCT07045311Triple-negative Breast Cancer

Drugs9MW2821·JS207·Albumin paclitaxel

Shanghai Junshi Bioscience Co., Ltd.

Phase 2

Hefei, Beijing, Guangzhou, Baoding, Harbin, Zhangzhou, Wuhan, Nanjing

2025-09-17

Recruiting

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

NCT07190209Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Hangzhou, Harbin

2025-09-16

Recruiting

Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)

NCT07215650Generalized Myasthenia Gravis

DrugCizutamig

Candid Therapeutics

Phase 1

Fuzhou, Guangzhou, Guiyang, Zhengzhou, Changchun, Shanghai, Taiyuan, Chengdu

2025-09-16

Recruiting

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy

DrugEmpasiprubart

argenx

Phase 3

160

Fuzhou, Guangzhou, Beijing, Xi'an

2025-09-16

Not yet open

PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy

NCT07174375Acute Ischemic Stroke

DrugsEvolocumab·Alirocumab·Biweekly

Nanfang Hospital, Southern Medical University

Phase 2/3

478

Fuzhou, Dongguan, Guangzhou, Heyuan, Hengzhou, Haikou, Ganzhou

2025-09-15

Not yet open

Episodic Future Thinking to Improve Anticoagulant Adherence in Atrial Fibrillation

NCT07174778Atrial Fibrillation (AF)

Jiawen You

Not applicable

Guangzhou

2025-09-15

Not yet open

A Prospective, Randomized, Multicenter Clinical Study Comparing Adjuvant Radiotherapy Versus Observation in High-risk Localized Adrenocortical Carcinoma After Surgery.

NCT07141147Radiotherapy, High-risk Localized Adrenocortical Carcinoma

Sun Yat-sen University

Not applicable

Guangzhou

2025-09-15

Recruiting

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

NCT07088263Breast Neoplasms

DrugUtidelone

Sun Yat-sen University

Phase 3

192

Guangzhou

2025-09-15

Recruiting

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

NCT07077512Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)

DrugSintilimab

Sun Yat-sen University

Phase 2

Guangzhou

2025-09-15

Active, closed

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

414

Beijing, Chengdu, Guangzhou, Hangzhou, Luoyang, Macau, Nanchang, Shanghai

2025-09-13

Recruiting

Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma

NCT07084662Diffuse Large B-Cell Lymphoma (DLBCL)

Sun Yat-sen University

Phase 2/3

Guangzhou

2025-09-11

Recruiting

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

NCT06919965Non-Muscle Invasive Bladder Neoplasms

DrugsErdafitinib·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

220

Beijing, Chengdu, Guangzhou, Nanjing, Ningbo, Tianjin, Wenzhou, Wuhan

2025-09-10

Recruiting

Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC

NCT07177794Esophageal Cancer, Chemoradiotherapy

DrugsJS001·Xeloda·Toripalimab·Capecitabine

Sun Yat-sen University

Phase 3

242

Guangzhou

2025-09-10

Not yet open

CVL006 Combination Therapy in Advanced Solid Tumors

NCT07157956Advanced Solid Tumor

DrugsEnfortumab Vedotin·Sacituzumab tirumotecan·Trastuzumab deruxtecan

Convalife (Shanghai) Co., Ltd.

Phase 1/2

318

Guangzhou

2025-09-10

Recruiting

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

NCT07029828Severe Alopecia Areata

DrugsRitlecitinib higher·Ritlecitinib lower

Pfizer

Phase 3

140

Beijing, Guangzhou, Changsha, Shanghai, Chengdu, Hangzhou

2025-09-10

Recruiting

A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

NCT07174908Non-Small Cell Lung Cancer

DrugsD-1553·IN10018

InxMed (Shanghai) Co., Ltd.

Phase 3

400

Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Gannan, Nanchang

2025-09-10

Recruiting

Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

NCT06824103Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease

DrugRuxolitinib

Novartis Pharmaceuticals

Phase 4

Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Zhengzhou, Wuhan, Nanjing

2025-09-09

Recruiting

A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)

NCT07136792Renal Anemia of Chronic Kidney Disease

DrugPegmolesatide

Guangdong Provincial People's Hospital

Not applicable

Beijing, Longyan, Zhangzhou, Guangzhou, Meizhou, Shantou, Shaoguan, Zhongshan

2025-09-08

Recruiting

Efficacy Evaluation of 5-Fluorouracil as an Adjuvant to Endoscopic Dacryocystorhinostomy in Managing Primary Acquired Nasolacrimal Duct Obstruction With Small Lacrimal Sac: A Randomized Controlled Study

NCT07154121Primary Acquired Nasolacrimal Duct Obstruction

Zhongshan Ophthalmic Center, Sun Yat-sen University

Not applicable

100

Guangzhou

2025-09-08

Recruiting

A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.

NCT07099430Advanced Melanoma

DrugsLBL-024·Toripalimab

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2

280

Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Nanjing, Changchun, Jinan

2025-09-05

Not yet open

AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment

NCT07158840Non-Small Cell Lung Cancer

DrugIvonescimab

Akeso

Phase 2

Guangzhou

2025-09-05

Recruiting

A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT07288554Chronic Obstructive Pulmonary Disease (COPD)

DrugBBT002

Bambusa Therapeutics

Phase 1

Hefei, Guangzhou, Jiangmen, Qingyuan, Xinxiang, Yichang, Xuzhou, Nanchang

2025-09-05

Recruiting

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsTacabrutideg·Pirtobrutinib

BeOne Medicines

Phase 3

500

Beijing, Fuzhou, Lanzhou, Guangzhou, Jiangmen, Nanning, Guiyang, Shijiazhuang

2025-09-04

Recruiting

A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

NCT07137910Chronic Hepatitis B

DrugAHB-137

Ausper Biopharma Co., Ltd.

Phase 2

200

Beijing, Jilin City, Chongqing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou

2025-09-04

Recruiting

Clinical Study of Cizutamig in Systemic Lupus Erythematosus

NCT07215663Systemic Lupus Erythematosus (SLE)

DrugCizutamig

Candid Therapeutics

Phase 1

Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai

2025-09-04

Recruiting

A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma

NCT07098403Asthma

DrugGSK5784283

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 3

408

Guangzhou

2025-09-03

Recruiting

Clinical Outcomes After Non-curative Endoscopic Resection in Early Colorectal Cancer: A Multicenter Study

NCT07542171Early Colorectal Cancer, Non-curative Endoscopic Resection

Nanfang Hospital, Southern Medical University

Observational

400

Guangzhou, Shenzhen, Haizhu

2025-09-03

Recruiting

The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes

NCT07156773Parkinson Disease

Guangzhou Novaken Pharm Co., Ltd.

Phase 2

Guangzhou

2025-09-03

Active, closed

A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B

NCT07135349Chronic Hepatitis B

Shanghai Argo Biopharmaceutical Co., Ltd.

Phase 2

209

Hefei, Beijing, Sichuan, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zunyi

2025-09-02

Recruiting

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

NCT07169994Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer

DrugsFurmonertinib Mesilate·YL202·Toripalimab

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1/2

414

Hefei, Fuzhou, Guangzhou, Meizhou, Nanning, Baoding, Harbin, Anyang

2025-09-02

Recruiting

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07164443Metastatic Castration-resistant Prostatic Neoplasms

DrugsJNJ-87189401·Pasritamig

Janssen Research & Development, LLC

Phase 3

1,203

Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Nanjing, Nanning, Nantong

2025-09-02

Recruiting

A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

NCT07093814Glioblastoma

DrugVRT106

Guangzhou Virotech Pharmaceutical Co., Ltd.

Phase 1/2

Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhuhai, Nanning, Jinan

2025-09-02

Recruiting

Clinical Multimodal Surveillance of Respiratory Syndrome Pathogens

NCT07694648Respiratory Tract Infections (RTI), Respiratory Syndrome, Acute, Severe, Acute Respiratory Infections (ARIs)

Huashan Hospital

Observational

2,398

Beijing, Guangzhou, Zhuhai, Shijiazhuang, Harbin, Jiamusi, Shangqiu, Zhengzhou

2025-09-01

Recruiting

Acupuncture and Compression for the Prevention of CIPN in Breast Cancer Patients

NCT07377279Breast Cancer, Chemotherapy-induced Peripheral Neuropathy (CIPN)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not applicable

384

Guangzhou

2025-09-01

Not yet open

Sivelestat Treatment for Postoperative Organ Protection in Type A Aortic Dissection

NCT07156656Type A Aortic Dissection, Organ Failure, Multiple

DrugSivelestat sodium

Shanghai Zhongshan Hospital

Phase 4

236

Hefei, Fuzhou, Guangzhou, Shenzhen, Xi'an, Shanghai

2025-09-01

Recruiting

The Electroencephalographic Mechanisms of Anesthesia and Human Consciousness

NCT07145697Consciousness, Level Altered

DrugDexmedetomidine

Guangzhou General Hospital of Guangzhou Military Command

Phase 4

Guangzhou

2025-09-01

Not yet open

Phase III Trial of Susu Zhike Granules in Children With Cold-cough Syndrome for Acute Cough Treatment

NCT06773117Cough

Tasly Pharmaceutical Group Co., Ltd

Phase 3

360

Hefei, Chongqing, Guangzhou, Zunyi, Xingtai, Kaifeng, Nanyang, Sanmenxia

2025-09-01

Not yet open

A Study on Cardiopulmonary Exercise Tolerance Standards for Healthy Chinese Population

NCT07108296Oxygen Consumption, Cardiorespiratory Fitness

Affiliated Hospital of Changchun University of Chinese Medicine

Observational

4,620

Beijing, Quanzhou, Guangzhou, Nanning, Daqing, Harbin, Puyang, Zhengzhou

2025-09-01

Recruiting

Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion

NCT07170345Hepatocellular Carcinoma (HCC), Microvascular Invasion (MVI)

Chinese Academy of Sciences

Observational

400

Fuzhou, Guangzhou, Zhuhai, Nanning, Guiyang, Zhengzhou, Shenyang, Chengdu

2025-09-01

Recruiting

Prospective Real-World Study of Pathology AI for Glioma Molecular Prediction

NCT07263711Glioma

Nanfang Hospital, Southern Medical University

Observational

2,000

Guangzhou

2025-09-01

Not yet open

PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis

NCT07119918Symptomatic Intracranial Atherosclerotic Stenosis

DrugRecaticimab

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

5,276

Guangzhou

2025-09-01

Recruiting

Multicenter Prospective Observational Study of Cardiotoxicity in Patients Receiving Targeted Cancer Therapies

NCT07058454Cancer;Cardiovascular;Adverse Events, Cancer

Sixth Affiliated Hospital, Sun Yat-sen University

Observational

5,000

Guangzhou

2025-09-01

Recruiting

We-INtervention Among Chinese HIV-serodiscordant Male Couples

NCT06639932HIV

City University of Hong Kong

Not applicable

320

Xiamen, Guangzhou, Shenzhen, Chengdu

2025-09-01

Not yet open

A Randomized Controlled Study on the Improvement of Medical Experience for Patients With Radiation-induced Oropharyngeal Mucositis Based on the RIS System of the Internet of Things

NCT07126457Head and Neck Cancer, Radiation-Induced Mucositis

Nanfang Hospital, Southern Medical University

Not applicable

110

Guangzhou, Huizhou, Jieyang, Meizhou

2025-09-01

Recruiting

Diagnostic Trial of a Vision Transformer-Based Ultrasound AI Model for Placenta Accreta Spectrum

NCT07643090Placenta Accreta Spectrum

FANG HE

Observational

561

Guangzhou

2025-09-01

Not yet open

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

NCT07040644Triple Negative Breast Neoplasms

DrugsSacituzumab Govitecan·Toripalimab·Nab-paclitaxel

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

150

Guangzhou

2025-09

Recruiting

Comparative Study of New Classification and Traditional Classification of Radioactive Oropharyngeal Mucositis

NCT06307327Head and Neck Cancer, Radiation-Induced Mucositis

Nanfang Hospital, Southern Medical University

Observational

264

Guangzhou, Huizhou, Jieyang, Meizhou

2025-09

Recruiting

Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI

NCT07181499NSCLC, Adjuvant Drug Therapy, EGFR

DrugsBefotertinib·Pemetrexed·Carboplatin

Betta Pharmaceuticals Co., Ltd.

Phase 2

Guangzhou, Zhuhai

2025-09

Not yet open

Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis

NCT07131150Idiopathic Pulmonary Fibrosis (IPF)

Ruijin Hospital

Phase 2

Beijing, Guangzhou, Shenzhen, Hebei, Zhengzhou, Wuhan, Changsha, Nanjing

2025-08-31

Recruiting

Node-Sparing Hypofractionated Radiotherapy Plus Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Randomized, Phase II Trial

NCT07230639Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2

Guangzhou

2025-08-30

Recruiting

The Study is Being Conducted to Evaluate the Efficacy and Safety of Dexmedetomidine Hydrochloride Microneedles for Preoperative Sedation in Children

NCT07168720Preoperative Sedation

Guangzhou Novaken Pharm Co., Ltd.

Phase 2

Guangzhou

2025-08-29

Recruiting

Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

NCT06841679Gastric or Gastroesophageal Junction Adenocarcinoma

DrugsUtidelone·Capecitabine·Oxaliplatin

Beijing Biostar Pharmaceuticals Co., Ltd.

Phase 2/3

778

Anyang, Guangzhou, Jinan, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou

2025-08-28

Not yet open

A Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever

NCT07126171Chikungunya Fever

Jiangsu Kanion Pharmaceutical Co., Ltd

Not applicable

400

Guangzhou

2025-08-28

Recruiting

Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection

NCT07146100Chronic Hepatitis B

Ausper Biopharma Co., Ltd.

Observational

200

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou

2025-08-28

Recruiting

Prospective Pathology Foundation Models

NCT07157618Pancancer

Nanfang Hospital, Southern Medical University

Observational

2,000

Guangzhou, Jinan

2025-08-28

Recruiting

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

NCT07093710Peripheral T Cell Lymphoma

DrugsMitoxantrone Hydrochloride Liposome·Golidocitinib·Chidamide

Sun Yat-sen University

Phase 1/2

101

Guangzhou

2025-08-27

Active, closed

Milk Free From A1-Type β-Casein on Inflammation, Gastrointestinal Tolerance, and Pregnancy Outcomes

NCT06980376Healthy Pregnant Women

a2 Milk Company Ltd.

Not applicable

100

Foshan, Guangzhou, Wuxi, Xuzhou, Chengdu

2025-08-25

Recruiting

Impact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients

NCT07126470Cataract, Retinitis Pigmentosa (RP)

Zhongshan Ophthalmic Center, Sun Yat-sen University

Not applicable

Guangzhou, Shenzhen, Wuhan

2025-08-25

Not yet open

Effect of Light-Blocking Lenses on Pediatric Hyperopia

NCT07142915Hyperopia

Zhongshan Ophthalmic Center, Sun Yat-sen University

Not applicable

156

Guangzhou

2025-08-25

Not yet open

Effect of Light-Blocking Lenses on Hyperopic Anisometropic Children

NCT07142928Anisometropia, Hyperopia

Zhongshan Ophthalmic Center, Sun Yat-sen University

Not applicable

Guangzhou

2025-08-25

Recruiting

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

NCT07154706Non-small Cell Lung Cancer (NSCLC)

DrugTaletrectinib

Nuvation Bio Inc.

Phase 3

180

Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Nantong, Nanchang

2025-08-21

Recruiting

AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

NCT06959524Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries

Boston Scientific Corporation

Not applicable

1,616

Beijing, Beijin, Guangzhou, Wuhan, Xi'an

2025-08-21

Recruiting

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

NCT07082686Relapsed or Refractory Mantle Cell Lymphoma (MCL)

DrugICP-248

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 2

Hefei, Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Zhengzhou

2025-08-21

Recruiting

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

NCT07058077Heterozygous Familial Hypercholesterolemia (HeFH)

DrugsEnlicitide Decanoate·Enlicitide

Merck Sharp & Dohme LLC

Phase 2/3

153

Beijing, Guangzhou, Shanghai, Hangzhou

2025-08-21

Recruiting

PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

NCT07133750CRC (Colorectal Cancer)

DrugPumitamig

Biotheus Inc.

Phase 2

100

Beijing, Guangzhou, Harbin, Wuhan, Changchun, Jinan, Shanghai, Chengdu

2025-08-19

Recruiting

DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

NCT07059650Diffuse Large B-Cell Lymphoma

DrugsR-GemOx·Birelentinib·R-Chop

Dizal Pharmaceuticals

Phase 1/2

150

Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan

2025-08-19

Not yet open

EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT07138989Nasopharyngeal Cancinoma (NPC)

Sun Yat-sen University

Phase 2

Guangzhou

2025-08-19

Recruiting

Study of CM512 Injection in Subjects With Moderate-to-severe Asthma

NCT07011524Asthma

DrugCM512

Keymed Biosciences Co.Ltd

Phase 2

200

Guangzhou

2025-08-19

Recruiting

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

NCT07086976Autoimmune Haemolytic Anaemia

DrugRilzabrutinib

Sanofi

Phase 3

Beijing, Chengde, Guangzhou, Hohhot, Nanchang, Suzhou, Tianjin, Wuhan

2025-08-18

Recruiting

Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer

NCT07037199Advanced Breast Cancer

DrugTrastuzumab Rezetecan

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Guangzhou

2025-08-18

Recruiting

Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation

NCT07158710Malignant Brain Tumors

DrugHSK42360

Haisco Pharmaceutical Group Co., Ltd.

Phase 1

159

Beijing, Fuzhou, Guangzhou, Changchun, Shanghai

2025-08-15

Not yet open

Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma

NCT07110558Nasopharyngeal Cancinoma (NPC)

DrugsToripalimab·Cisplatin

Sun Yat-sen University

Phase 2

Guangzhou

2025-08-15

By invitation

A Bidirectional Study of Individualized Postoperative Adjuvant Treatment Decision Model for Locally Advanced Head and Neck Squamous Cell Carcinoma Based on Multimodal Dynamic Data

NCT07532928Deep Learning, Head & Neck Squamous Cell Carcinoma

Nanfang Hospital, Southern Medical University

Observational

571

Guangzhou

2025-08-15

Recruiting

Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer

NCT07095023Breast Cancers

DrugsPertuzumab/Trastuzumab·Paclitaxel

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not applicable

112

Beijing, Guangzhou, Shantou, Nanning, Guiyang, Haikou, Wenzhou, Shenzhen

2025-08-15

Recruiting

Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma

NCT07125755Squamous Cell Cancer of Head and Neck (SCCHN)

DrugCisplatin

Sun Yat-sen University

Phase 3

386

Guangzhou, Guilin, Sanya, Changsha, Nanjing

2025-08-15

By invitation

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

NCT07376629TNBC

DrugsHB0025·Nab-paclitaxel

Huabo Biopharm Co., Ltd.

Phase 2

Anyang, Changsha, Chengdu, Fujian, Guangdong, Guangzhou, Hangzhou, Harbin

2025-08-14

Recruiting

Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users

NCT07092709Acute Ischemic Stroke

DrugsTenecteplase (TNK)·Maximum

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

912

Guangzhou

2025-08-14

Recruiting

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06948318Immune Thrombocytopenic Purpura (ITP)

DrugMezagitamab

Takeda

Phase 3

150

Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang

2025-08-14

Active, closed

Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC

NCT07703228NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IIIB~IV, Second-line Therapy, Metastases

DrugsAnlotinib·Sacituzumab tirumotecan

Nanfang Hospital, Southern Medical University

Phase 2

Guangzhou

2025-08-13

Recruiting

Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome

NCT06896708Chronic Coronary Syndrome

Liu yong

Not applicable

766

Chongqing, Dongguan, Guangzhou, Shenzhen, Zhongshan, Dalian

2025-08-12

Recruiting

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

NCT06947967Lymphoma, T-Cell, Peripheral

DrugTucidinostat

Chipscreen Biosciences, Ltd.

Phase 3

224

Guangzhou

2025-08-12

Active, closed

Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)

NCT07246889Chronic Hepatitis B

DrugAHB-137

Ausper Biopharma Co., Ltd.

Phase 3

577

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou

2025-08-12

Recruiting

A Study of HDM2020 in Patients With Advanced Solid Tumors

NCT07098052Solid Tumor

DrugHDM2020

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 1

Guangzhou

2025-08-11

Recruiting

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

NCT07239947Atopic Dermatitis

DrugBBT001

Bambusa Therapeutics

Phase 1

Hefei, Wuhu, Beijing, Guangzhou, Changsha, Wuxi, Zhenjiang, Nanchang

2025-08-09

Recruiting

Effects of Acute Sleep Deprivation on Individuals With Different APOE Genotypes

NCT07085754Sleep, Sleep Deprivation

Yuhui Qiu

Not applicable

Guangzhou

2025-08-08

Active, closed

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

NCT07162181Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma

DrugPirtobrutinib

Eli Lilly and Company

Phase 2

Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan

2025-08-07

Recruiting

A Study of AK146D1 for Injection in Advanced Solid Tumors

NCT07067567Advanced Solid Tumors

DrugAK146D1

Akeso

Phase 1

200

Guangzhou

2025-08-07

Recruiting

Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal Dialysis

NCT07098351Adverse Event, Peritoneal Dialysis, Moderate-to-severe Pruritus, Chronic Kidney Disease-associated Itch

Guangdong Provincial People's Hospital

Not applicable

Guangzhou

2025-08-07

Recruiting

Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients

NCT06892093HER2-positive Breast Cancer, Diarrhea Caused by Drug, Neratinib

DrugLoperamide

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not applicable

308

Guangzhou

2025-08-07

Recruiting

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

NCT07098338Non-Small Cell Lung Cancer

DrugsRamucirumab·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

278

Changsha, Chengdu, Deyang, Dongguan, Fuzhou, Guangzhou, Hangzhou, Hefei

2025-08-07

Recruiting

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803Prostate Cancer

DrugsPrednisolone/prednisone·Saruparib·Abiraterone

AstraZeneca

Phase 3

700

Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Jinhua

2025-08-06

Recruiting

Interventional Left Ventricular Assist System for PCI in CHIP Patients

NCT07053618High-Risk Percutaneous Coronary Intervention (High-risk PCI), Left Ventricular Assist Devices

Suzhou Hengruihongyuan Medical Technology Co. LTD

Not applicable

286

Beijing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Changsha, Suzhou, Nanchang

2025-08-06

Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068Type 1 Diabetes Mellitus

DrugsTzield·Teplizumab

Sanofi

Phase 3

723

Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hohhot

2025-08-06

Recruiting

Discontinuation of Anticoagulation With Intensive Rhythm Monitoring in Post-ablation Patients With Atrial Fibrillation

NCT06871228Atrial Fibrillation (AF)

Beijing Anzhen Hospital

Not applicable

4,100

Hefei, Beijing, Guangzhou, Shijiazhuang, Harbin, Luohe, Zhengzhou, Wuhan

2025-08-05

Active, closed

To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice

NCT07029451Infertility

Ferring Pharmaceuticals

Observational

2,549

Hefei, Ma’anshan, Beijing, Chaoyang, Xicheng, Guangzhou, Shantou, Nanning

2025-08-05

Active, closed

Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

NCT07081633Hepatocellular Carcinoma

DrugsTremelimumab·Durvalumab

AstraZeneca

Phase 2

114

Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing

2025-08-05

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis

NCT07038382Membranous Nephropathy, Lupus Nephritis (LN)

Shanghai Henlius Biotech

Phase 2

Beijing, Changsha, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing

2025-08-05

Recruiting

Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation

NCT06615596Atrial Fibrillation (AF)

China National Center for Cardiovascular Diseases

Early Phase 1

3,160

Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Shanghai, Taiyuan, Chengdu

2025-08-05

Recruiting

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965Breast Cancer

DrugsPrifetrastat·Exemestane·Everolimus·Fulvestrant

Pfizer

Phase 3

400

Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin, Wuhan

2025-08-05

Recruiting

MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.

NCT07391839Hepatoma, Unresectable Hepatocellular Carcinoma (HCC)

Suzhou Mednovo Yi Medical Technology Co., Ltd.

Phase 1

Hefei, Fuzhou, Guangzhou, Nanjing, Jinan, Hangzhou, Henan, Shanghai

2025-08-04

Recruiting

A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

NCT07060989Advanced Solid Tumors

Nutshell Therapeutics (Shanghai) Co., LTD.

Phase 1/2

220

Beijing, Guangzhou, Nanchang, Shanghai, Xi'an

2025-08-04

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07005102Non-Squamous Non-Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab Adizutecan·Osimertinib·Pemetrexed·Cisplatin

AbbVie

Phase 2/3

854

Beijing, Fuzhou, Guangzhou, Wuhan, Nanchang, Shanghai, Chengdu

2025-08-03

Recruiting

Mechanism and Effect of Novel Metabolites on Valvular Heart Disease

NCT07065500Valvular Heart Disease

Sun Yat-sen University

Observational

4,000

Guangzhou

2025-08-01

Recruiting

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

NCT07314723Urothelial Carcinoma

Drugs9MW2821·Toripalimab

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 2

Guangzhou

2025-08-01

Active, closed

Active Families, Healthy Minds: A Family-Centered School Physical Activity Program for Early Adolescents

NCT07380750Adolescent Mental Health, Physical Inactivity, Mental Well-being, Sedentary Behavior

Jinan University Guangzhou

Not applicable

345

Guangzhou

2025-08-01

Recruiting

Selective Total Mesorectal Excision Based on Intra-Operative Frozen Section From Local Excision in Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy

NCT07337811Rectal Cancer Patients

Sun Yat-sen University

Not applicable

Guangzhou

2025-08-01

Not yet open

A Real-World Study About Anemia in Chronic Kidney Disease in China（DASHENG）

NCT07098416Anemia in Chronic Kidney Disease

Wei Chen

Observational

20,000

Guangzhou

2025-08-01

Active, closed

Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma

NCT07488533Non-Clear Cell Renal Cell Carcinoma

DrugsFruquintinib·Serplulimab

Sun Yat-sen University

Phase 2

Guangzhou

2025-08-01

Not yet open

Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity

NCT07072000Nasopharyngeal Cancinoma (NPC)

Hai-Qiang Mai,MD,PhD

Phase 3

550

Foshan, Guangzhou, Zhangjiang, Liuzhou, Wuzhou

2025-08-01

Not yet open

YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study2

NCT07034807Diabetic Kidney Disease (DKD)

Liu Hongfang

Not applicable

228

Beijing, Guangzhou, Changchun, Tianjin

2025-08-01

Recruiting

Assessment of DOT Spectacles in Chinese Children Extension

NCT07008001Juvenile Myopia, Myopia

SightGlass Vision, Inc.

Not applicable

175

Changsha, Chengdu, Guangzhou, Shanghai, Tianjin

2025-08-01

Not yet open

Human-AI Collaborative INSIGHT Diagnostic Workflow for in Breast Cancer With Extensive Intraductal Component

NCT07060599Artificial Intelligence (AI) in Diagnosis

Sun Yat-sen University

Not applicable

480

Guangzhou

2025-08-01

Not yet open

29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness

NCT07100236Primary Hepatocellular Carcinoma

Junjie Xu

Observational

350

Hefei, Chaoyang, Fuzhou, Guangzhou, Zhengzhou, Shanghai, Hangzhou, Wenzhou

2025-08-01

Not yet open

YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study1

NCT07032116Diabetic Kidney Disease (DKD)

Liu Hongfang

Observational

4,472

Beijing, Guangzhou, Changchun, Tianjin

2025-08-01

Not yet open

PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006)

NCT07090707HNSCC, PD-1, Radiotherapy

DrugPD-1inhibitor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Guangzhou

2025-08-01

Recruiting

Efficacy Analysis of Personalized-Target Transcranial Magnetic Stimulation (TMS) in the Treatment of Chronic Tinnitus: A Single-Center, Single-Blind Randomized Clinical Trial

NCT07267455Chronic Tinnitus

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not applicable

116

Guangzhou

2025-08-01

By invitation

Retrospective Pathology Foundation Models

NCT07239297Pancancer

Nanfang Hospital, Southern Medical University

Observational

2,000

Guangzhou, Jinan

2025-08-01

Active, closed

Acute Myocardial Infarction Prediction Using Artificial Intelligence Applied to Electrocardiogram Images

NCT07163767Acute Myocardial Infarction (AMI), Electrocardiography, Artifical Intelligence

Guangdong Provincial People's Hospital

Observational

150,000

Guangzhou

2025-08-01

Recruiting

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

NCT07119996Bladder (Urothelial, Transitional Cell) Cancer

DrugsTislelizumab·Gemcitabine·Cisplatin

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 1

Guangzhou

2025-08-01

Active, closed

A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma

NCT07138885Hepatocellular Carcinoma (HCC), Second Line Treatment

Sun Yat-sen University

Phase 2

Guangzhou

2025-08-01

Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

NCT07044336Endometrial Cancer, Malignant Solid Tumour

DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel

AstraZeneca

Phase 3

800

Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou

2025-08-01

Not yet open

Iparomlimab and Tuvonralimab Combined With 2 or 4 Cycles of Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC

NCT07129161Carcinoma, Non-Small-Cell Lung

DrugAlbumin-Bound Paclitaxel

Sun Yat-sen University

Phase 2

Guangzhou, Xi'an

2025-08

Not yet open

Evaluating the Efficacy of Hyperthermic Intraperitoneal Treatment to Enhance the Sensitivity of Immune Checkpoint Inhibitor in Patients With Advanced Ovarian Cancer： A Single-arm Study

NCT07068178HIPEC, Ovarian Serous Adenocarcinoma

Jing Li

Phase 2

Guangzhou

2025-08

Not yet open

Acupuncture Combined With Chemotherapy for Gastric Cancer After Surgery

NCT07098949Gastric Cancer

Guangzhou University of Traditional Chinese Medicine

Not applicable

346

Guangzhou

2025-08

Not yet open

Evaluation of ICP-B794 in Patients With Advanced Solid Tumors

NCT07136558Advanced Solid Tumors

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 1

410

Guangzhou

2025-08

Not yet open

A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults

NCT07083739Primary Immune Thrombocytopenia

DrugTQB3473

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

320

Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Zhanjiang

2025-08

Active, closed

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

NCT07029711Severe Alopecia Areata

DrugsRitlecitinib higher·Ritlecitinib lower

Pfizer

Phase 3

208

Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Chengdu, Kunming, Hangzhou

2025-07-31

Not yet open

Traditional Chinese Medicine Intervention for Ischemic Cardiovascular Disease Comorbid With Diabetes Mellitus: An Efficacy Comparative Study

NCT07088523Diabete Mellitus, Ischemic Cardiovascular Disease

Guangzhou University of Traditional Chinese Medicine

Phase 4

4,205

Guangzhou

2025-07-31

Recruiting

A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

NCT07124936Diffuse Large B Cell Lymphoma (DLBCL)

DrugsHDM2005·Rituximab Biosimilar·Doxorubicin·Prednisone

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 1/2

Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan, Changsha

2025-07-30

Recruiting

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

NCT06721013Immune Thrombocytopenia (ITP)

DrugPirtobrutinib

Eli Lilly and Company

Phase 1/2

Guangzhou, Jinan, Tianjin, Wuhan

2025-07-30

Recruiting

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

NCT07079475Non-Small Cell Lung Cancer

DrugsDZD6008·Sunvozertinib·Osimertinib

Dizal Pharmaceuticals

Phase 1/2

220

Beijing, Guangzhou, Harbin, Changsha, Nanjing, Shengyang, Jinan, Shanghai

2025-07-30

Recruiting

TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer

NCT07044908RAS/BRAF Wild Type Colorectal Cancer

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 1/2

Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Meizhou, Shantou, Nanning

2025-07-30

Recruiting

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

NCT06911502Follicular Lymphoma

DrugsPrednisone/Prednisolone·Golcadomide·Bendamustine·Vincristine

Celgene

Phase 3

400

Beijing, Fuzhou Fujian, Guangzhou, Harbin, Wuhan, Changsha, Hohhot, Suzhou

2025-07-28

Recruiting

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

NCT07071519Ulcerative Colitis

DrugRisankizumab

AbbVie

Phase 3

120

Guangzhou, Zhengzhou, Changsha, Changchun, Shanghai, Hangzhou

2025-07-28

Active, closed

Clinical Research Cohort for Polycystic Ovary Syndrome

NCT07739940PCOS (Polycystic Ovary Syndrome)

Guangdong Women and Children Hospital

Observational

420

Guangzhou

2025-07-28

Recruiting

Real-World Study on Chinese Medicine for Treating Chikungunya Fever

NCT07120724Chikungunya Fever

Guangzhou University of Traditional Chinese Medicine

Observational

600

Guangzhou

2025-07-26

Recruiting

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

NCT07047365HER2-positive Advanced Breast Cancer

DrugsTQB2930·Trastuzumab

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 3

416

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen

2025-07-25

Active, closed

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

12,800

Bengbu, Beijing, Guangzhou, Huizhou, Yulin, Qinhuangdao, Shijiazhuang, Harbin

2025-07-25

Recruiting

Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease

NCT07213765Mycobacterium Avium Complex Pulmonary Disease

DrugsAzithromycin·Ethambutol·Linezolid·Rifampicin

Bin Cao

Phase 4

188

Hefei, Beijing, Guangzhou, Nanchang, Shanghai

2025-07-24

Recruiting

a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）

NCT07128797NAFLD (Non-alcoholic Fatty Liver Disease), NASH (Nonalcoholic Steatohepatitis)

Tasly Biopharmaceuticals Co., Ltd.

Phase 1

Beijing, Guangzhou, Datong, Tianjin, Wenzhou

2025-07-24

Recruiting

Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors

NCT07073534Patients With Advanced or Metastatic Malignant Tumors

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 1/2

203

Guangzhou

2025-07-24

Recruiting

Prevention of Recurrence With Cordyceps Sinensis in Mycobacterium Avium Complex Pulmonary Disease

NCT07174076Mycobacterium Avium Complex Pulmonary Disease

Bin Cao

Phase 4

300

Hefei, Beijing, Guangzhou, Nanchang, Shanghai

2025-07-24

Recruiting

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsSigvotatug vedotin·Pembrolizumab

Pfizer

Phase 3

714

Hefei, Beijing, Fuzhou, Guangzhou, Huizhou, Nanning, Harbin, Luoyang

2025-07-23

Recruiting

A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

NCT07024173Locally Advanced Breast Cancer, Metastatic Breast Cancer

DrugsHRS-8080·Exemestane·Anastrozole·Everolimus

Shandong Suncadia Medicine Co., Ltd.

Phase 3

240

Guangzhou, Changsha

2025-07-23

Active, closed

A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer

NCT07071714Colorectal Cancer

DrugsSHR-8068·Adebrelimab·Bevacizumab

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

103

Guangzhou

2025-07-22

Recruiting

Prospective Cohort Study on Oral Microbiome Changes in Patients With Locally Advanced Oral Squamous Cell Carcinoma Following Neoadjuvant Chemoimmunotherapy

NCT07111455Locally Advanced Oral Squamous Cell Carcinoma

Zhujiang Hospital

Observational

Guangzhou

2025-07-22

Recruiting

Prediction of Postoperative Recurrence in Crohn's Disease

NCT07824791Crohn Disease (CD), Postoperative Recurrence and Metastasis

Sixth Affiliated Hospital, Sun Yat-sen University

Observational

250

Guangzhou

2025-07-22

Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807Breast Neoplasms

DrugsPatritumab deruxtecan·Pegylated liposomal doxorubicin·Abraxane·Xeloda

Merck Sharp & Dohme LLC

Phase 3

1,000

Hefei, Beijing, Chongqing, Wanzhou, Fujian, Guangzhou, Jiangmen, Nanning

2025-07-21

Recruiting

Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

NCT07086469Toripalimab, Surufatinib, Neoadjuvant Immunochemotherapy, Chemoradiotherapy

DrugSurufatinib Administration

Sun Yat-sen University

Phase 2

Guangzhou

2025-07-20

Not yet open

GnRH Agonist Pretreatment Duration and Letrozole Supplementation in Frozen Embryo Transfer for Adenomyosis Patients

NCT07065539Adenomyosis of Uterus, Frozen Embryo Transfer (FET)

DrugGnRH-a

First Affiliated Hospital, Sun Yat-Sen University

Not applicable

432

Guangzhou

2025-07-20

Not yet open

Study of Peripheral Blood CHI3L1 to Predict Tumor Response to Radiotherapy

NCT07071688Tumor, Radiotherapy, Biomarker

Nanfang Hospital, Southern Medical University

Observational

338

Guangzhou, Huizhou, Meizhou

2025-07-20

Recruiting

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

NCT07086456Surufatinib, Tislelizumab, Concurrent Chemoradiotherapy, Consolidation Therapy

DrugsSurufatinib·Tislelizumab

Sun Yat-sen University

Phase 2

Guangzhou

2025-07-20

Not yet open

Correlation of Dry Eye Disease, Problematic Smartphone Use and Sleep Quality in Adolescents and Young Adults

NCT07020871Dry Eye Disease (DED)

Wei XIA, PhD

Observational

453

Guangzhou

2025-07-20

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants

NCT07005713Chronic Spontaneous Urticaria

DrugTacabrutideg

BeOne Medicines

Phase 1

Beijing, Chongqing, Guangzhou, Wuhan, Changsha, Qingdao, Chengdu, Hangzhou

2025-07-19

Recruiting

CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study

NCT07072494Acute Lymphoblastic Leukemia

Zhujiang Hospital

Phase 1/2

Guangzhou

2025-07-19

Recruiting

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

NCT06929273Bipolar Disorder Type I With Mania

DrugsValproate·Lamotrigine·Lithium·KarXT

Bristol-Myers Squibb

Phase 3

450

Beijing, Guangzhou, Baoding, Changsha, Nanjing, Xi'an, Chengdu, Tianjin

2025-07-18

Active, closed

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm

DrugBesremi

PharmaEssentia

Phase 3

160

Beijing, Chongqing, Guangdong, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing

2025-07-18

Recruiting

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

NCT07071337Metastatic Breast Cancer

DrugsSacituzumab tirumotecan·Nab-paclitaxel·Capecitabine·Paclitaxel

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3

430

Beijing, Guangzhou

2025-07-18

Recruiting

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

NCT06824168Acute Myeloid Leukemia, Leukemia

DrugQuizartinib

Daiichi Sankyo

Phase 2

130

Beijing, Changchun, Guangzhou, Hangzhou, Nanchang, Nanjing, Nanning, Qingdao

2025-07-18

Recruiting

The Outcome of Chronic Kidney Disease Patients With Obstructive Sleep Apnea Syndrome

NCT06971874Chronic Kidney Diseases, OSAS (Obstructive Sleep Apneas Syndrome)

Nanfang Hospital, Southern Medical University

Observational

356

Guangzhou

2025-07-17

Recruiting

A Study of MHB046C Injection in Patients With Advanced Solid Tumors

NCT06985355Advanced Solid Cancer

Minghui Pharmaceutical (Hangzhou) Ltd

Phase 1/2

200

Guangzhou

2025-07-17

Recruiting

Study on Repeat Liposomal Bupivacaine for Post-Surgery Pain in Anal Fistula Patients.

NCT07081373Anal Fistula

Sixth Affiliated Hospital, Sun Yat-sen University

Not applicable

408

Guangzhou

2025-07-16

Recruiting

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma

DrugsLeucovorin/levofolinate calcium·Bevacizumab biosimilar·Calderasib·Mvasi

Merck Sharp & Dohme LLC

Phase 3

477

Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Xiamen, Guangzhou, Shenzhen

2025-07-16

Recruiting

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

NCT06963827Kidney Disease

DrugMezagitamab

Takeda

Phase 3

347

Beijing, Changping, Xiamen, Guangdong, Guangzhou, Shenzhen, Changsha, Baotou

2025-07-15

Recruiting

A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors

NCT07043751Advanced Malignant Tumors

DrugTQB6411

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 1

216

Beijing, Dongguan, Guangdong, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha

2025-07-15

Not yet open

A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests

NCT07087041Decompensated Cirrhosis, Hepatitis B Virus (HBV) Infection, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Alcohol-Related Liver Disease

Beijing Friendship Hospital

Observational

735

Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Zhuhai, Guiyang, Shiyan

2025-07-15

Active, closed

A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)

NCT06963710Chronic Hepatitis B Infection

DrugALG-000184

Aligos Therapeutics

Phase 2

200

Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Nanjing, Shanghai

2025-07-15

Not yet open

A Multicenter, Randomized, Double-Blind, Controlled Clinical Study of Minocycline for the Treatment of Retinitis Pigmentosa

NCT07082855Retinitis Pigmentosa, Inherited Retinal Dystrophy, Retina Disorder

DrugMinocycline

Zhongshan Ophthalmic Center, Sun Yat-sen University

Phase 3

126

Guangzhou

2025-07-15

Recruiting

Novel Humanized Ferritin-Based NIR Fluorescent Probe for Identifying Sentinel Lymph Node Metastasis in Early Gastric Cancer

NCT07294638Gastric Cancer, Molecular Imaging

Nanfang Hospital, Southern Medical University

Observational

Guangzhou

2025-07-15

Recruiting

Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta

NCT07025954Placenta Previa, Placenta Accreta Spectrum, Antepartum Bleeding, Emergency Cesarean Section

The Third Affiliated Hospital of Guangzhou Medical University

Not applicable

600

Guangzhou, Zhengzhou, Chengdu, Beijing, Chongqing

2025-07-12

Not yet open

Fasting-Mimicking Diet as an Adjunct to Neoadjuvant Chemotherapy for Hormone-Receptor-Positive Breast Cancer

NCT07077018Fasting-Mimicking Diet, Breast Cancer, Neoadjuvant Chemotherapy

Guangdong Provincial People's Hospital

Not applicable

Guangzhou

2025-07-12

Not yet open

Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer

NCT07059338HER2 Positive, Colorectal Cancer (CRC)

DrugsTrastuzumab·Irinotecan·Cetuximab

Sun Yat-sen University

Phase 2

Guangzhou

2025-07-11

Recruiting

This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

NCT06862206Chronic Obstructive Pulmonary Disease

AstraZeneca

Observational

1,000

Anhui, Anning, Beijing, Binzhou, Changzhou, Fenyang, Guangdong, Guangzhou

2025-07-11

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

NCT07011732Alzheimer Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

426

Beijing, Haidian District, Chongqing, Guangzhou, Shenzhen, Changsha, Nanjing, Shanghai

2025-07-10

Recruiting

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

NCT06953323Advanced Solid Tumor

DrugsWJB001·Niraparib·Paclitaxel·Bevacizumab

Wigen Biomedicine Technology (Shanghai) Co., Ltd.

Phase 1/2

Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Hangzhou

2025-07-10

Not yet open

Development and Improvement of Home Rehabilitation Scheme for Preschool Children With Congenital Heart Disease After Operation

NCT07055334Heart Defects, Congenital, Rehabilitation, Preschool Child, Qualitative Research

Wei XIA, PhD

Observational

Guangzhou

2025-07-10

Recruiting

Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC

NCT07386158Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC), Neoadjuvant Therapy

Sun Yat-sen University

Phase 2

Guangzhou

2025-07-10

Active, closed

Artificial Intelligence Diagnosis of Different Histopathological Growth Patterns of Colorectal Cancer Liver Metastasis

NCT07088393Liver Metastases of Colorectal Cancer

Sun Yat-sen University

Observational

437

Guangzhou

2025-07-09

Recruiting

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

NCT06802835Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma, Metastatic Nasopharyngeal Carcinoma

DrugGemcitabine/Cisplatin

Sun Yat-sen University

Phase 1/2

148

Guangzhou

2025-07-09

Recruiting

MITRIS China Post Market Clinical Follow-up (PMCF) Study

NCT07059793Mitral Valve Replacement

Edwards Lifesciences

Observational

250

Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Xi'an, Jinan

2025-07-08

Active, closed

A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

NCT06975722Ulcerative Colitis

DrugBrivekimig

Sanofi

Phase 2

105

Huizhou, Guangzhou, Nanjing, Suzhou, Wuxi, Shanghai, Hangzhou, Ningbo

2025-07-07

Recruiting

The Safety and Efficacy of GMDTC for Injection in Subjects With Elevated Cadmium Levels

NCT07057414Cadmium Exceeds the Standard

DrugGmdtc

Guangdong Jianersheng Pharmaceutical Technology Co., Ltd.

Phase 2

Guangzhou

2025-07-07

Recruiting

A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive

NCT06930794Non-Small Cell Lung Cancer

DrugVebreltinib

Beijing Pearl Biotechnology Limited Liability Company

Phase 3

300

Beijing, Guangzhou

2025-07-07

Recruiting

The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

NCT07064681Resectable Hepatocellular Carcinoma With High Risk of Recurrence

Sun Yat-sen University

Observational

100

Guangzhou

2025-07-05

Active, closed

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

NCT07483450Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis

DrugOcrelizumab

Hoffmann-La Roche

Phase 4

Nanchang, Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hohhot

2025-07-04

Recruiting

A Study on the Biomechanical Mechanisms of Orthotic/Physical Training Correction of Hallux Valgus and Its Impact on the Lower Limbs

NCT07036120Hallux Valgus Deformity

Wan Xinzhu

Not applicable

Guangzhou

2025-07-03

Recruiting

Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial

NCT06976229Spinal Cord Injury, Safety, Clinical Trials, Efficacy

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

Phase 1

Guangzhou

2025-07-02

Active, closed

Feasibility of Multi-cancer Early Detection Test in Screening Population (NQMD-CS)

NCT07834268Colorectal Cancer, Grastic Cancer, Esophageal Cancer, Lung Cancer

Fifth Affiliated Hospital of Guangzhou Medical University

Not applicable

1,250

Guangzhou, Huizhou

2025-07-02

Recruiting

Post-Market Clinical Study to Evaluate the Safety and Effectiveness of REFLEX ULTRA 45 for Coblation Inferior Turbinate Reduction in China

NCT07025304Nasal Obstruction Due to Inferior Turbinate Hypertrophy

Smith & Nephew, Inc.

Not applicable

105

Guangzhou, Zhengzhou, Nanjing, Changchun, Hangzhou

2025-07-02

Recruiting

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

NCT06859762Advanced Solid Tumor

DrugBevacizumab

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1

630

Beijing, Guangzhou, Harbin, Nanchang, Shenyang, Jinan, Shanghai, Tianjin

2025-07-02

Recruiting

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT07052903Transthyretin Amyloidosis With Cardiomyopathy

DrugNucresiran

Alnylam Pharmaceuticals

Phase 3

1,750

Binhai, Changsha, Chengdu, Dongcheng, Fuzhou, Guangzhou, Haidian, Hangzhou

2025-07-02

Recruiting

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

NCT07177352Alzheimers Disease

Hoffmann-La Roche

Phase 3

80,000

Beijing, Xuzhou, Changchun, Chengdu, Chongqing, Guangzhou, Hefei, Nanjing

2025-07-02

Active, closed

Reducing the Resection Range After Neoadjuvant Therapy for Locally Advanced Upper Rectal and Rectosigmoid Junction Cancers

NCT07038122Locally Advanced Rectal Carcinoma

Sixth Affiliated Hospital, Sun Yat-sen University

Not applicable

874

Guangzhou

2025-07-01

Recruiting

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

NCT06855277Prostate Cancer

DrugsAAA817·ARPI

Novartis Pharmaceuticals

Phase 3

940

Fuzhou, Guangzhou, Wuhan, Nanjing, Shenyang, Chengdu, Hangzhou, Beijing

2025-07-01

Not yet open

Patient Journey in Advanced Gynecologic Cancers

NCT07015593Genital Neoplasms, Female, Uterine Cervical Neoplasms, Endometrial Carcinoma

Tongji Hospital

Observational

780

Hefei, Guangzhou, Wuhan, Chongqing

2025-07-01

Not yet open

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

NCT07061717Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

DrugsHydroxychloroquine·Palbociclib

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

474

Guangzhou

2025-07-01

Not yet open

Super-Pulsed Thulium Fiber Laser Versus Holmium:YAG Laser in Retrograde Intrarenal Surgery for Upper Ureteral and Renal Stones

NCT07012941Ureterolithiasis, Renal Calculi

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not applicable

448

Guangzhou

2025-07-01

Recruiting

Mesenteric Surgical Margin for Crohn's Disease Endoscopic Recurrence

NCT06241170Endoscopic Recurrence Rate, After Ileocolic Crohn 's Disease Surgery

Sixth Affiliated Hospital, Sun Yat-sen University

Not applicable

172

Guangzhou

2025-07-01

Recruiting

Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC

NCT07052669Locally Advanced Non-Small Cell Lung Cancer

Sun Yat-sen University

Phase 3

311

Chongqing, Lanzhou, Guangzhou

2025-07-01

Recruiting

Safety and Efficacy of Ventricular Irrigation for Ventriculitis

NCT06358209Central Nervous System Infections

RenJi Hospital

Not applicable

310

Hefei, Wuhu, Beijing, Fuzhou, Guangzhou, Shenzhen, Zhongshan, Harbin

2025-07-01

Active, closed

18F-FDG PET/CT Radiomics Models for Precision Diagnosis and Prognosis in NSCLC

NCT07449858Non Small Cell Lung Cancer

Second Affiliated Hospital, Zhejiang University, School of Medicine

Observational

500

Guangzhou, Shenyang, Chengdu, Hangzhou

2025-07-01

Not yet open

ScreenTalk to Improve Colorectal Cancer Screening Uptake Among First-degree Relatives of Patients: a Study Protocol

NCT06710860Colonoscopy, Colorectal Cancer, First-degree Relatives

Sun Yat-sen University

Not applicable

314

Guangzhou

2025-07

Not yet open

Multimodal Biomarkers in Prediction of Diabetic Retinopathy

NCT07098832Diabetic Retinopathy (DR)

Zhongshan Ophthalmic Center, Sun Yat-sen University

Observational

1,538

Guangzhou

2025-07

Not yet open

A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC

NCT07038460Resectable Non-small Cell Lung Cancer

DrugsLimertinib·Osimertinib·Sintilimab

Wen-zhao ZHONG

Phase 2

134

Guangzhou, Changsha, Hangzhou

2025-07

Recruiting

A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors

NCT07071090Solid Tumor Malignancies

Heronova Pharmaceuticals

Phase 1

Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha, Jinan, Hangzhou

2025-06-30

Recruiting

FSRT Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocarcinoma

NCT07058428Multiple Brain Metastases in Lung Adenocarcinoma

DrugBevacizumab

Sun Yat-Sen University Cancer Center

Phase 3

258

Guangzhou

2025-06-30

Not yet open

Efficacy of the Ranger Drug-Coated Balloon in Treating BTK Lesions in Patients With CLTI

NCT07014475Chronic Limb Threatening Ischemia

First Affiliated Hospital, Sun Yat-Sen University

Observational

700

Guangzhou

2025-06-30

Recruiting

Transanal Total Mesorectal Excision vs Robotic Total Mesorectal Excision

NCT07651553Rectal Cancer Patients, Robotic Assisted Intervention

Sun Yat-sen University

Not applicable

216

Guangzhou

2025-06-30

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms

DrugsEpirubicin·Adriamycin·Xeloda·Paraplatin

Merck Sharp & Dohme LLC

Phase 3

2,400

Hefei, Beijing, Xiamen, Guangzhou, Jiangmen, Liuzhou, Nanning, Xingtai

2025-06-30

Recruiting

Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial

NCT07003620Cervical Cancers

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Guangzhou

2025-06-29

Recruiting

A Retrospective Analysis of Robot-Assisted Versus Endoscopic Breast-Conserving Surgery for Breast Cancer

NCT07321145Breast Cancer, Breast Surgery

Sixth Affiliated Hospital, Sun Yat-sen University

Not applicable

200

Guangzhou

2025-06-27

Recruiting

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT07082738Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca

Phase 2

987

Baotou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou

2025-06-27

Recruiting

Study of CM518D1 in Patients With Advanced Solid Tumors

NCT07019779Advanced Solid Tumors

Keymed Biosciences Co.Ltd

Phase 1/2

434

Guangzhou

2025-06-27

Recruiting

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

5,056

Hefei, Beijing, Guangzhou, Haikou, Qinhuangdao, Shijiazhuang, Daqing, Harbin

2025-06-25

Active, closed

A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD

NCT06843408Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 1/2

Beijing, Chengdu, Chongoing, Guangzhou, Hangzhou, Shanghai, Tianjin, Wuhan

2025-06-25

Active, closed

Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma

NCT06673693Head and Neck Squamous Cell Carcinoma (HNSCC), HNSCC

DrugTislelizumab

Sun Yat-sen University

Phase 2

Guangzhou

2025-06-25

Recruiting

A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors

NCT07028268For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

210

Guangzhou

2025-06-24

Recruiting

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

NCT07070479Recurrent or Metastatic Nasopharyngeal Carcinoma

DrugsMitoxantrone Hydrochloride Liposome·Venetocalx·Irinotecan liposome·Nimotuzumab

Ming-Yuan Chen

Phase 2

208

Guangzhou, Zhongshan, Zhuhai, Changsha

2025-06-24

Recruiting

A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening

NCT07032961Gastritis, Gastric Dysplasia, Gastric Ulcer, Gastric Cancer

Nanfang Hospital, Southern Medical University

Observational

10,000

Guangzhou

2025-06-24

Recruiting

A Study in Children With Achondroplasia

NCT07301463Achondroplasia

Abbisko Therapeutics Co, Ltd

Observational

260

Beijing, Guangzhou, Zhengzhou, Wuhan, Shanghai, Chengdu, Hangzhou

2025-06-20

Recruiting

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

NCT06991257Heart Failure

DrugPF-07328948

Pfizer

Phase 2

620

Beijing, Lanzhou, Guangzhou, Haikou, Shijiazhuang, Changsha, Changchun, Xi'an

2025-06-19

Active, closed

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744Ulcerative Colitis

DrugsRisankizumab·Vedolizumab

AbbVie

Phase 3

573

Hefei, Beijing, Chongqing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha

2025-06-17

Recruiting

The Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast Reconstruction

NCT06995118Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Du Zhenggui

Not applicable

337

Fuzhou, Guangzhou, Anyang, Zhengzhou, Changsha, Hohhot, Suzhou, Nanchang

2025-06-17

Recruiting

Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis

NCT06707194Spondyloarthritis (SpA), Ankylosing Spondylitis (AS)

DrugsBenzathine Penicillin·Etanercept

Nanfang Hospital, Southern Medical University

Phase 4

340

Hefei, Chongqing, Guangzhou, Hohhot, Ganzhou

2025-06-14

Active, closed

Study of ZG005 in Patients With Advanced Solid Tumors

NCT06927687Advanced Solid Tumor

DrugZG005

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2

Guangzhou

2025-06-13

Recruiting

ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

NCT07327034Hepatocellular Carcinoma (HCC)

DrugABSK-011

Abbisko Therapeutics Co, Ltd

Phase 2

141

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guilin, Liuzhou, Nanning

2025-06-13

Recruiting

A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors

NCT06990698Advanced Solid Tumors

Zhuhai Fapon Biopharma Co., Ltd.

Phase 1

108

Guangzhou, Wuhan, Nanchang, Taiyuan, Hangzhou

2025-06-12

Recruiting

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsSonrotoclax·Venclexta·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

630

Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Shijiazhuang, Harbin

2025-06-11

Recruiting

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

NCT06783647Advanced Solid Tumour

DrugsLBL-024·Pemetrexed·Docetaxel·Paclitaxel

Nanjing Leads Biolabs Co.,Ltd

Phase 2

250

Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Guilin, Nanning, Harbin

2025-06-11

Recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568Endometrial Cancer

DrugsDoxorubicin·Docetaxel·Paclitaxel

BioNTech SE

Phase 3

480

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shantou

2025-06-10

Recruiting

A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China

NCT06931691Paroxysmal Nocturnal Hemoglobinuria

DrugIptacopan

Novartis Pharmaceuticals

Observational

Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nantong, Nanchang, Changchun

2025-06-10

Not yet open

The Influence of Central Sensitization in Endometriosis Disease

NCT07014761Endometriosis, Adenomatosis

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Observational

200

Guangzhou

2025-06-10

Recruiting

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

NCT06993844Advanced Solid Tumors, Advanced Breast Cancer

DrugFulvestrant

Ensem Therapeutics

Phase 1/2

233

Beijing, Fuzhou, Guangzhou, Shandong, Shanghai

2025-06-10

Recruiting

SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population

NCT07051603Uncontrolled Hypertension

DrugSAL0140

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Phase 1

Guangzhou

2025-06-09

Recruiting

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 3

1,755

Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei

2025-06-09

Active, closed

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

NCT06956235Hidradenitis Suppurativa

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 2

149

Guangzhou, Changsha, Changchun, Shanghai, Ürümqi, Hangzhou

2025-06-09

Recruiting

A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations

NCT06947811EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor

DrugsAlmonertinib·Palbociclib

Sun Yat-sen University

Phase 1/2

Guangzhou

2025-06-09

Recruiting

A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs

NCT07069569Chronic Hepatitis B

DrugsHepatitis B Vaccine·Peg-IFNα·AHB-137

Ausper Biopharma Co., Ltd.

Phase 2

200

Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zunyi, Wuhan, Changchun

2025-06-08

Recruiting

External Mastalgia-oil Versus Placebo in Premenopausal Women With Severe Mastalgia

NCT06966245Mastalgia

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

190

Guangzhou

2025-06-08

Recruiting

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

NCT06946927NSCLC (Advanced Non-small Cell Lung Cancer)

DrugsJMKX001899·IN10018·Carboplatin

Jemincare

Phase 1

Guangzhou

2025-06-06

Not yet open

Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus

NCT06966830Epilepsy, Status Epilepticus

DrugLacosamide

Second Affiliated Hospital of Guangzhou Medical University

Observational

100

Guangzhou

2025-06-06

Recruiting

A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

NCT06891833HER2-positive Breast Cancer

DrugsT-Bren·Pertuzumab·Trastuzumab·Docetaxel

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2/3

985

Bengbu, Hefei, Chongqing, Fuzhou, Guangzhou, Shenzhen, Liuzhou, Nanning

2025-06-05

Active, closed

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

NCT06872125Dravet Syndrome

DrugZorevunersen

Stoke Therapeutics, Inc

Phase 3

170

Beijing, Guangzhou, Wuhan

2025-06-04

Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222Leukemia, Myeloid, Acute

DrugsBleximenib·Azacitidine·Venetoclax

Janssen Research & Development, LLC

Phase 3

600

Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan

2025-06-04

Recruiting

PeRsonalized Blood prEssure Management on Postoperative Complications and Mortality in hIgh-risk Patients Undergoing Major Non-cardiac Surgery

NCT06952387Hypotension

Nanfang Hospital, Southern Medical University

Not applicable

1,624

Guangzhou, Shenzhen, Zhuhai, Xi’an, Hangzhou

2025-06-03

Recruiting

Omitting CTV for Primary Tumor in LS-SCLC

NCT07008716SCLC, Limited Stage, Radiation Exposure, Radiotherapy Side Effect, Progression

DrugsEtoposide·Cisplatin·Carboplatin

Sun Yat-sen University

Phase 3

852

Guangzhou, Hangzhou

2025-06-03

Recruiting

AI-Assisted MRE for Intestinal Fibrosis in Crohn's Disease

NCT06858553Crohn Disease (CD)

Minhu Chen

Observational

234

Guangzhou, Nanjing, Huangpu, Hangzhou

2025-06-03

Recruiting

A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease

NCT06958536Crohn's Disease

DrugBrivekimig

Sanofi

Phase 2

Changsha, Changzhou, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang

2025-06-03

Recruiting

Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer

NCT06903858Colorectal Cancer, Microsatellite Instability High, Mismatch Repair Deficiency

DrugsCelecoxib·Toripalimab

Sun Yat-sen University

Phase 2

105

Guangzhou

2025-06-01

Not yet open

New Triple Therapy in Newly Diagnosed Type 2 Diabetes

NCT06946628Diabetes Mellitus

Sun Yat-sen University

Phase 3

296

Guangzhou

2025-06-01

Recruiting

ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC

NCT07012954Colorectal Cancer Metastatic

DrugsErbitux·Trifluridine/Tipiracil·Avastin·Cetuximab

Sun Yat-sen University

Phase 1/2

Guangzhou

2025-06-01

Recruiting

Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer

NCT07358182Trastuzumab-rezetecan, HER2-low Breast Cancer, HER2-positive Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Observational

300

Guangzhou

2025-06-01

Recruiting

Association of Inflammatory Factors With Complications in the Diabetic Population: a Cross-sectional Study

NCT06651983Diabetes Mellitus

Nanfang Hospital, Southern Medical University

Observational

3,000

Guangzhou

2025-06-01

Active, closed

Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell Carcinoma

NCT07881900Non-Clear Cell Renal Cell Carcinoma

DrugsSunitinib·Benmelstobart·Anlotinib

Sun Yat-sen University

Phase 3

126

Guangzhou

2025-06-01

Not yet open

Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL

NCT06890585BTK Inhibitors, Histone Deacetylase Inhibitor, Double Express Diffuse Large B-cell Lymphoma

DrugR-Chop

Li Zhiming

Phase 2

128

Guangzhou

2025-06-01

Recruiting

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

NCT07150247BRAF V600 Colorectal Cancer

DrugsIparomlimab and Tuvonralimab·Avastin·Irinotecan·Adrucil

Sun Yat-sen University

Phase 2

Guangzhou

2025-06-01

Recruiting

Intraoperative Rectal Lavage to Prevent Local Recurrence After Laparoscopic Mid-to-Low Rectal Cancer Resection: A Multicenter Randomized Trial

NCT07512232Middle and Low Rectal Cancer, Rectal Cancer Surgery

Sun Yat-sen University

Not applicable

1,598

Guangzhou

2025-06-01

Recruiting

A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure

NCT07047547Hemodialysis Complication, Heart Failure

DrugVericiguat

Guangdong Provincial People's Hospital

Not applicable

118

Guangzhou

2025-06-01

Recruiting

Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus

NCT07374328Type 2 Diabetes

DrugsSitagliptin·Semaglutide

Second Affiliated Hospital of Guangzhou Medical University

Phase 1/2

240

Guangzhou

2025-06-01

Recruiting

Effect of Dezocine Versus Nalbuphine Combined With Sufentanil on Postoperative Analgesia, Complications, and Free Flap Survival in Patients Undergoing Oral Cancer Radical Surgery: A Randomized Controlled Clinical Trial.

NCT07401641Oral Cancer, Postoperative Pain Management, Free Tissue Flaps, Mouth Neoplasms

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not applicable

Guangzhou

2025-06-01

Active, closed

Development and Clinical Application of ApoC3 Protein as a Predictive Biomarker for Insulin Resistance in Polycystic Ovary Syndrome

NCT07739953PCOS (Polycystic Ovary Syndrome)

Guangdong Women and Children Hospital

Observational

200

Guangzhou

2025-06-01

Not yet open

A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)

NCT06959693Metastatic Colorectal Cancer (CRC)

DrugsEnvafolimab·MFOLFOX6

Sun Yat-sen University

Phase 2/3

590

Guangzhou

2025-06-01

Active, closed

Pelvic Floor Peritoneal Closure to Prevent Postoperative Ileus in Mid-Low Rectal Cancer Surgery

NCT07432542Rectal Cancer Surgery, Middle and Low Rectal Cancer, Intestinal Obstruction, Ileus

Sun Yat-sen University

Not applicable

516

Guangzhou

2025-06-01

Not yet open

Extent of Lymph Node Dissection for Advanced Right-Sided Colon Cance

NCT06986538Advanced Right-sided Colon Cancer, the Extent of Lymph Node Dissection

Sixth Affiliated Hospital, Sun Yat-sen University

Not applicable

1,064

Beijing, Fuzhou, Guangzhou, Qingyuan, Shaoguan, Zhaoqing, Nanning, Guiyang

2025-06-01

Recruiting

A Prospective Cohort Study on Visual Function and Psychological Conditions Before and After Surgery for Congenital Ptosis

NCT07534436Ptosis

Zhongshan Ophthalmic Center, Sun Yat-sen University

Observational

Guangzhou

2025-06-01

Not yet open

Node-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC)

NCT06980389Immune Checkpoint Therapy, Radiotherapy, Metastatic Gastric Carcinoma

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2

176

Guangzhou

2025-05-31

Recruiting

Diagnostic Value of Confocal Laser Endomicroscopy (CelTouch) for Peripheral Lung Lesions

NCT07004946Peripheral Pulmonary Lesion

Guangzhou Medical University

Observational

286

Guangzhou

2025-05-31

Recruiting

JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia

NCT06940960B Acute Lymphoblastic Leukemia, B-Non Hodgkin Lymphoma

DrugJY231

Affiliated Hospital of Guangdong Medical University

Not applicable

Guangzhou

2025-05-30

Not yet open

Effect of Vegan Diet on Microbiome and Metabolism

NCT07003230Vegan Diet

Zhujiang Hospital

Not applicable

Guangzhou

2025-05-30

Active, closed

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

NCT06970743Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsChlorambucil·Tacabrutideg·Bendamustine·Methylprednisolone

BeOne Medicines

Phase 3

153

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shenzhen, Nanning

2025-05-29

Recruiting

A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

NCT06764615Crohn's Disease, Ulcerative Colitis

DrugZasocitinib

Takeda

Phase 2

192

Chongqing, Guangdong, Guangzhou, Shanghai

2025-05-28

Recruiting

HW071021 Monotherapy in Patients With Advanced Solid Tumors

NCT06882135Advanced Solid Tumors

Wuhan Humanwell Innovative Drug Research and Development Center Limited Company

Phase 1

Guangzhou

2025-05-28

Recruiting

A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors

NCT06943677Advanced Malignant Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1

Beijing, Guangzhou, Zhengzhou, Nanjing, Nanchang, Xi'an, Heze, Jinan

2025-05-26

Not yet open

Investigation Into the Safety and Efficacy of ICG-Labeled Fluorescence Imaging Technology in Guiding the Resection of Bone and Soft Tissue Tumors

NCT06979115Bone Neoplasms, Soft Tissue Neoplasms

DrugIndocyanine Green

Guangdong Provincial People's Hospital

Observational

Guangzhou

2025-05-25

Active, closed

A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China

NCT06588153Glucocorticoid-induced Osteoporosis

DrugsProlia·Denosumab

Amgen

Phase 4

102

Beijing, Guangzhou, Shenzhen, Luoyang, Wuhan, Changzhou, Huaian, Nantong

2025-05-24

Recruiting

One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors

NCT06781125Malignant Solid Tumors

Immorna Biotherapeutics, Inc.

Phase 1/2

Guangzhou

2025-05-23

Recruiting

Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

NCT07023484Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma

DrugsPaclitaxel·Carboplatin

The University of Hong Kong

Phase 2

126

Guangzhou, Shenzhen

2025-05-22

Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504Endometrial Cancer

DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

1,123

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang

2025-05-22

Recruiting

An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors

NCT06942143Sarcoma, Lung Cancers, Melanoma

DrugNY-ESO-1 TCR-T

Guangzhou FineImmune Biotechnology Co., LTD.

Phase 1

Guangzhou

2025-05-22

Recruiting

Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma

NCT06912698Nasopharyngeal Cancinoma (NPC)

Hai-Qiang Mai,MD,PhD

Phase 3

342

Guangzhou

2025-05-22

Recruiting

A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin

Astellas Pharma Global Development, Inc.

Phase 3

500

Hefei, Fuzhou, Guangzhou, Harbin, Zhenngzhou, Wuhan, Xining, Shanghai

2025-05-22

Recruiting

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

NCT06962800Primary Membranous Nephropathy

DrugsFelzartamab·Tacrolimus

Biogen

Phase 3

180

Fuyang, Beijing, Xichengqu Beijing, Xiamen, Lanzhou, Guangzhou, Shenzhen, Nanning

2025-05-22

Active, closed

JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

NCT06944470NSCLC

DrugsJS207·Paclitaxel

Shanghai Junshi Bioscience Co., Ltd.

Phase 2

Guangzhou

2025-05-20

Recruiting

Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors

NCT06938880Advanced Solid Tumor

DrugsZGGS18·ZG005

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2

Guangzhou

2025-05-20

Recruiting

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

NCT06977581Asthma

DrugTilrekimig

Pfizer

Phase 2

252

Beijing, Guangzhou, Baotou, Hohhot, Najing, Nanjing, Xuzhou, Nanchang

2025-05-20

Active, closed

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT06972472Obesity, Overweight, Type 2 Diabetes

DrugOrforglipron

Eli Lilly and Company

Phase 3

600

Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi

2025-05-19

Recruiting

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

NCT06711887Lupus Nephritis

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

348

Guangzhou, Shantou, Shenzhen, Liuzhou, Wuhan, Changchun, Shenyang, Binzhou

2025-05-19

Recruiting

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

NCT06830798Delayed Graft Function, DGF, Kidney Transplant

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

450

Guangzhou, Hangzhou, Hengyang, Nanning, Shenzhen, Taiyuan, Tianjin, Zhengzhou

2025-05-19

Recruiting

Bidirectional Cohort Study of Nanfang Spondyloarthritis

NCT06988813Spondyloarthritis (SpA), Ankylosing Spondylitis (AS)

Nanfang Hospital, Southern Medical University

Observational

3,000

Guangzhou

2025-05-17

Recruiting

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

NCT06947993Atopic Dermatitis

Novartis Pharmaceuticals

Phase 2

224

Guangzhou, Shantou, Changsha, Changchun, Hangzhou, Beijing, Shanghai

2025-05-16

Recruiting

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

NCT06912711Nasopharyngeal Carcinoma

DrugsNimotuzumab·Toripalimab

Sun Yat-sen University

Phase 2

Guangzhou

2025-05-16

Recruiting

A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors

NCT06954077Gastrointestinal Tumor, Solid Tumor

DrugBL-M09D1

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 1

Guangzhou

2025-05-15

Recruiting

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

NCT06957886HER2-low Breast Cancer

DrugsT-Bren·Albumin paclitaxel

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3

566

Guangzhou, Changsha

2025-05-15

Active, closed

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

NCT06972459Obesity, Overweight

DrugOrforglipron

Eli Lilly and Company

Phase 3

800

Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi

2025-05-15

Recruiting

Safety and Efficacy of Pucotenlimab in pLECC

NCT06969534Lymphoepithelioma-like Carcinoma, Lymphoepithelioma, Carcinoma

DrugPucotenlimab

Sun Yat-sen University

Phase 2

Guangzhou

2025-05-15

Recruiting

Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Cancer Who Are Inactive Hepatitis B Carriers

NCT06966232Gastrointestinal Cancers

DrugEntecavir

Sun Yat-sen University

Phase 3

136

Guangzhou

2025-05-15

Not yet open

Magnesium-L-Threonate Improves Menopausal Symptoms

NCT06959745Menopause Syndrome, Magnesium

Guangdong Provincial People's Hospital

Not applicable

Guangzhou

2025-05-15

Active, closed

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

NCT06993792Obesity, Overweight, Type 2 Diabetes

DrugOrforglipron

Eli Lilly and Company

Phase 3

1,400

Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi

2025-05-15

Recruiting

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

NCT06990867Acute Ischemic Stroke

Corxel Pharmaceuticals

Phase 2/3

740

Baotou, Beijing, Changchun, Guangzhou, Harbin, Kaili, Linfen, Nanyang

2025-05-15

Recruiting

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

NCT06925737Prostate Cancer, Prostatic Neoplasms

DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

1,440

Beijing, Chongqing, Fuzhou, Guangzhou, Zhuhai, Nanning, Zhengzhou, Wuhan

2025-05-13

Active, closed

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

NCT06934044Multiple Myeloma

DrugsCevostamab·Tocilizumab

Hoffmann-La Roche

Phase 1

Guangzhou, Tianjin, Nanchang, Wenzhou, Wuhan

2025-05-13

Recruiting

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819891Moderately to Severely Active Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 3

425

Ganzhou, Jinhua, Beijing, Chengdu, Guangzhou, Haikou, Huai'an, Huizhou

2025-05-12

Active, closed

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

NCT06925750Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

130

Guangzhou, Changsha, Shanghai, Kunming

2025-05-12

Recruiting

A Study of ZL-1310 in Participants With Selected Solid Tumors

NCT06885281Solid Tumors

DrugZL-1310

Zai Lab (Shanghai) Co., Ltd.

Phase 1/2

166

Beijing, Xiamen, Guangzhou, Harbin, Changsha, Changchun, Shanghai

2025-05-12

Recruiting

PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC

NCT06977074Non-small Cell Lung Cancer (NSCLC)

Sun Yat-sen University

Phase 2

Guangzhou

2025-05-10

Recruiting

Risk Assessment for HBV-Related Liver Cancer

NCT07160946HBV-related Liver Cirrhosis

Sun Yat-sen University

Observational

6,000

Guangzhou

2025-05-10

Recruiting

ICP-332 in Subjects With Non-segmental Vitiligo

NCT07047612Non Segmental Vitiligo

DrugICP-332

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 2/3

603

Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Luoyang, Nanyang

2025-05-09

Recruiting

A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients

NCT06911827Advanced Solid Tumor

DrugPembrolizumab

Qilu Pharmaceutical Co., Ltd.

Phase 1/2

149

Guangzhou

2025-05-09

Recruiting

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06935357Immunoglobulin A Nephropathy (IgAN)

DrugFelzartamab

Biogen

Phase 3

454

Fuyang, Hefei, Beijing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen

2025-05-08

Recruiting

Immediate Angioplasty For Acute Ischemic Stroke With Severe Intracranial Atherosclerotic Stenosis

NCT06437600Stroke, Acute Ischemic

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not applicable

412

Guangzhou, Shenzhen

2025-05-08

Active, closed

Phase I Trial of QH-1A Hybrid Bio-Artificial Liver With Ex Vivo Blood-Purifying MSCs in Acute-on-Chronic Liver Failure

NCT06996392Acute-On-Chronic Liver Failure

Third Affiliated Hospital, Sun Yat-Sen University

Phase 1

Guangzhou

2025-05-07

Recruiting

Crisugabalin for Radiotherapy-Related Neuropathic Pain

NCT06766916Neuropathic Pain

DrugsCrisugabalin·Pregabalin

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

172

Fuzhou, Guangzhou, Zhongshan, Nanning, Zhengzhou, Changsha

2025-05-07

Not yet open

Aspirin 150 mg vs 100 mg for Prevention of Preeclampsia in High-Risk Obese Pregnant Women

NCT06952712Preeclampsia

DrugAspirin

FANG HE

Phase 3

1,300

Guangzhou

2025-05-07

Recruiting

A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT06976190Recurrent or Metastatic Nasopharyngeal Carcinoma

DrugsPucotenlimab·Becotatug Vedotin·Capecitabine

Lepu Biopharma Co., Ltd.

Phase 3

446

Guangzhou

2025-05-06

Recruiting

Safety and Efficacy of Exercise in Type-B Aortic Dissection

NCT07009067Type B Aortic Dissection

Guangdong Provincial People's Hospital

Not applicable

Guangzhou

2025-05-06

Recruiting

Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)

NCT06958432Rectal Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2/3

430

Guangzhou

2025-05-06

Not yet open

Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer

NCT06861712Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Stereotactic Body Radiation Therapy (SBRT)

Sun Yat-sen University

Phase 2

Guangzhou

2025-05-06

Recruiting

A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

NCT06952699Narcolepsy Type 2

DrugTAK-360

Takeda

Phase 2

Beijing, Guangzhou, Changchun, Shanghai

2025-05-06

Recruiting

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

NCT06749899Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer

DrugsLenvatinib·Gemcitabine·Cisplatin

Sun Yat-Sen University Cancer Center

Phase 3

580

Fuzhou, Dongguan, Foshan, Guangzhou, Zhongshan, Nanning, Guiyang, Wuhan

2025-05-04

Recruiting

Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads

NCT06947356Hepatitis B

Guangzhou 8th People's Hospital

Not applicable

210

Guangzhou, Shenzhen, Shijiazhuang, Changsha, Wenzhou, Beijing

2025-05-03

Recruiting

Efficacy and Safety of rTMS Combined With HA in the Treatment of Cognitive Decline in Aged Related Hearing Loss

NCT07389213Senile Deadness

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not applicable

189

Guangzhou

2025-05-01

Not yet open

China Chronic Cough Registry: a Multicenter, Prospective, Observational Study

NCT06862362Chronic Cough (CC)

The First Affiliated Hospital of Guangzhou Medical University

Observational

6,000

Guangzhou

2025-05-01

Recruiting

An AI Educational Agent for Medical Machine Learning Courses

NCT07449182Medical Education, Artificial Intelligence in Medicine

Sun Yat-sen University

Not applicable

Guangzhou

2025-05-01

Recruiting

CHina Adrenal Venous saMPling InvestigatiON

NCT07252284Hyperaldosteronism, Adrenal Venous Sampling, Adrenalectomy

Chinese Academy of Medical Sciences, Fuwai Hospital

Observational

5,000

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou

2025-05-01

Recruiting

Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)

NCT06958419Immune Checkpoint Therapy, Radiotherapy, Metastatic Colorectal Cancer (CRC)

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2/3

286

Guangzhou

2025-05-01

Recruiting

Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children

NCT06904729Lupus Nephritis

Guangzhou Women and Children's Medical Center

Phase 3

Guangzhou

2025-05-01

Not yet open

Laparoscopic Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) for Colorectal Liver Metastases (CRLM)

NCT06779474Colorectal Liver Metastases

Yanhong Deng

Observational

Guangzhou

2025-05-01

Recruiting

The Impact of MTM Model on the Efficacy and Safety of Anticoagulant Therapy in Postoperative Colorectal Cancer Patients

NCT06998745Thrombosis, Venous

Sixth Affiliated Hospital, Sun Yat-sen University

Not applicable

327

Guangzhou

2025-05-01

Not yet open

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

NCT06900218Nasopharyngeal Carcinoma (NPC)

DrugsSintilimab·Capecitabine

Sun Yat-sen University

Phase 3

664

Guangzhou

2025-05-01

Recruiting

Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma

NCT06933394Neuroblastoma

DrugArsenic Trioxide

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Guangzhou

2025-05-01

Recruiting

Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK）

NCT07005570pMMR/MSS Locally Advanced Rectal Cancer

Dechang Diao

Phase 2

Guangzhou

2025-05-01

Not yet open

Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma

NCT06429397Pheochromocytoma

DrugAnlotinib and Benmelstobart

Sun Yat-sen University

Phase 2

Guangzhou

2025-05-01

Recruiting

The Impact of Breathing Training on PPSUI: A Randomized Controlled Trial

NCT06623617Stress Urinary Incontinence (SUI)

Jie Li

Not applicable

Guangzhou

2025-05-01

Not yet open

Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A

NCT06961500Follicular Lymphoma Grade 3A

DrugsCHOP·Bendamustine·Obinutuzumab

Sun Yat-sen University

Phase 2

133

Guangzhou

2025-05-01

Not yet open

A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis

NCT06958861Acute Exacerbations of Bronchiectasis

Shanghai Huilun Pharmaceutical Co., Ltd.

Phase 2

180

Fuyang, Hefei, Fuzhou, Guangzhou, Shenzhen, Baise City, Shijiazhuang, Nanyang

2025-05

Not yet open

An Interpretable Fundus Diseases Report Generating System Based On Weakly Labelings

NCT06918028Retinal Diseases, Choroidal Disease, Pathological Myopia, Diabetic Retinopathy

Zhongshan Ophthalmic Center, Sun Yat-sen University

Observational

9,999

Guangzhou

2025-05

Recruiting

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

NCT06862869Carcinoma, Non-Small-Cell Lung

DrugAlectinib

Hoffmann-La Roche

Observational

800

Zhanjiang, Guangzhou, Kaifeng, Zhengzhou, Ürümqi, Beijing, Changsha, Changzhou

2025-04-30

Recruiting

A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia

NCT06900920Primary Immune Thrombocytopenia

DrugTQB3473

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

199

Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Zhanjiang

2025-04-30

Not yet open

Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

NCT06957561Bladder Cancer, Muscle-invasive Bladder Cancer

DrugDisitamab Vedotin

Sun Yat-sen University

Phase 1/2

Guangzhou

2025-04-30

Recruiting

Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.

NCT06911684Rectal Cancer Patients

Sun Yat-sen University

Phase 2

Guangzhou

2025-04-30

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

NCT06884618Neoplasms

Hoffmann-La Roche

Phase 1

405

Guangzhou, Shanghai, Wuhan

2025-04-30

Recruiting

Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines

NCT06937944Moderate to Severe Glabellar Lines

DrugsOnabotulinumtoxinA·Botox

JHM BioPharma (Tonghua) Co. , Ltd.

Phase 3

669

Beijing, Chongqing, Guangzhou, Shijiazhuang, Changsha, Xuzhou, Shanghai, Xianyang

2025-04-30

Recruiting

Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

NCT06963281Solid Tumors

Fortvita Biologics (USA)Inc.

Phase 1

285

Guangzhou, Jinan, Taiyuan

2025-04-29

Recruiting

Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy

NCT06817265Non-Proliferative Diabetic Retinopathy

Beletalent (Zhuhai) Pharmaceutical Co., Ltd

Phase 3

360

Xuancheng, Beijing, Guangzhou, Shenzhen, Zhuhai, Guiyang, Shijiazhuang, Kaifeng

2025-04-29

Recruiting

Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study

NCT07806292Unresectable Hepatocellular Carcinoma

DrugAnlotinib

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Guangzhou

2025-04-28

Recruiting

The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature

NCT06927310Idiopathic Short Stature

DrugsInpegsomatropin·Recombinant Human Growth Hormone

Xiamen Amoytop Biotech Co., Ltd.

Phase 3

300

Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Wuhan

2025-04-28

Recruiting

A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC

NCT06925516Intrahepatic Cholangiocarcinoma (Icc)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Guangzhou

2025-04-25

Recruiting

Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

NCT06414460Locally Advanced/Metastatic Solid Tumors

InSilico Medicine Hong Kong Limited

Phase 1/2

146

Beijing, Guangzhou, Nanjing, Shanghai

2025-04-25

Recruiting

Protein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder

NCT06763848Neuromyelitis Optica Spectrum Disorders

DrugMethylprednisolone

Third Affiliated Hospital, Sun Yat-Sen University

Not applicable

144

Guangzhou

2025-04-25

Recruiting

Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma

NCT06970145Craniopharyngiomas

DrugAnlotinib

Nanfang Hospital, Southern Medical University

Phase 1/2

Guangzhou

2025-04-25

Active, closed

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

NCT06929624Diffuse Large B-cell Lymphoma

DrugsRituximab·Oxaliplatin·Gemcitabine

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

282

Beijing, Guangzhou

2025-04-24

Recruiting

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

NCT06880770Severe Hypertriglyceridemia

DrugPlozasiran

Arrowhead Pharmaceuticals

Phase 3

288

Beijing, Guangzhou, Guiyang, Harbin, Luoyang, Nanyang, Zhuzhou, Baotou

2025-04-24

Active, closed

Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma

NCT07047001Renal Cell Carcinoma (RCC), Adjuvant

DrugsVorolanib·Toripalimab

Dong Wen

Phase 2

Guangzhou

2025-04-24

By invitation

Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients

NCT06908473Metabolic Syndrome, Cardiovascular Disease (CKD), Cerebrovascular Disease, Qi Deficiency and Blood Stasis

Guangdong Provincial Hospital of Traditional Chinese Medicine

Phase 3

530

Guangzhou

2025-04-24

Recruiting

Correlation and Predictive Research of Metal Elements in Radiation-Induced Oral Mucositis

NCT06968520Head and Neck Tumors, Metal, Copper, Radiotherapy-Induced Oral Mucositis

Nanfang Hospital, Southern Medical University

Observational

383

Guangzhou

2025-04-24

Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

NCT06875310Carcinoma, Non-Small-Cell Lung

DrugsAdagrasib·Pemetrexed·Keytruda·Cisplatin

Mirati Therapeutics Inc.

Phase 3

630

Bengbu, Hefei, Beijing, Chongqing, Fuzhou Fujian, Xiamen, Guangzhou, Shantou

2025-04-24

Recruiting

A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia

NCT06898255Cancer Cachexia

DrugGFS202A

Genfleet Therapeutics (Shanghai) Inc.

Phase 1

Guangzhou

2025-04-24

Recruiting

Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma

NCT06829771Diffuse Large B Cell Lymphoma

DrugsTQB2825·R-Chop·Lenvatinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2

Bengbu, Ma’anshan, Beijing, Fuzhou, Quanzhou, Lanzhou, Guangzhou, Liuzhou

2025-04-23

Recruiting

Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study)

NCT07025590Cardiovascular Diseases (CVD), Depression Anxiety Disorder

Guangdong Provincial People's Hospital

Not applicable

106

Guangzhou

2025-04-22

Active, closed

PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer

NCT06933251Locally Advanced Rectal Cancer (LARC)

Guangdong Provincial People's Hospital

Phase 2

Guangzhou

2025-04-20

Recruiting

Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）

NCT06924398Lung Cancer (NSCLC)

Sun Yat-sen University

Phase 2

Guangzhou

2025-04-20

Recruiting

A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma

NCT06860971Thyroid Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

144

Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Gui'lin, Liuzhou

2025-04-18

Not yet open

GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma

NCT06605131Nasopharyngeal Cancinoma (NPC)

DrugsCCRT·Toripalimab

Sun Yat-sen University

Phase 2

Guangzhou

2025-04-17

Recruiting

Effectiveness of a Lifestyle Intervention for Pregnant Women With Abnormal Glucose Metabolism in Early Pregnancy: EAGM Trial

NCT06767722Early Pregnancy, Fasting Plasma Glucose, Hemoglobin A1c Protein, Human, Lifestyle Intervention

First Affiliated Hospital, Sun Yat-Sen University

Not applicable

3,430

Guangzhou

2025-04-16

Recruiting

Electrical Impedance Tomography-Based Prognostic Model for ARDS

NCT06967207Acute Respiratory Distress Syndrome (ARDS), Ventilator-induced Lung Injury

XiaoJing Zou,MD

Observational

625

Guangzhou, Wuhan, Shanghai

2025-04-15

Active, closed

Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere

NCT06900543Unresectable Hepatocellular Carcinoma

DrugSIRT

Chengdu New Radiomedicine Technology Co. LTD.

Phase 3

108

Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Shenyang, Xi’an, Chengdu

2025-04-15

Recruiting

Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial

NCT06919380Anti-MDA5 Positive Dermatomyositis-Associated RP-ILD, Rapidly Progressive Interstitial Lung Disease

Li Shiyue

Phase 1

Guangzhou

2025-04-15

Active, closed

A Retrospective Clinical Study Exploring Prognostic Factors in Esophageal Cancer Patients

NCT06960889Esophageal Cancer (EsC)

Nanfang Hospital, Southern Medical University

Observational

500

Guangzhou

2025-04-15

Recruiting

Clinical Study on the Healing of Distal Radius Fractures With Conservative Treatment Assisted by Fu's Subcutaneous Needling

NCT07054463Distal Radius Fractures

Guangzhou University of Chinese Medicine

Not applicable

Guangzhou

2025-04-15

Recruiting

Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma

NCT06827717Ewing Sarcoma

DrugsIrinotecan liposome·Fluzoparib·Temozolomide

Sun Yat-sen University

Phase 2

Guangzhou

2025-04-15

Recruiting

A Study of HS-20122 in Patients With Advanced Solid Tumors

NCT06927570Advanced Solid Tumors

DrugHS-20122

Hansoh BioMedical R&D Company

Phase 1

1,050

Guangzhou

2025-04-15

Recruiting

Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma

NCT06846489Mantle Cell Lymphoma (MCL)

DrugsAcalabrutinib·Rituximab

Sun Yat-sen University

Phase 2

Guangzhou

2025-04-14

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

NCT06858813Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer

DrugLenvatinib

AbbVie

Phase 1

232

Guangzhou, Shanghai

2025-04-14

Recruiting

5-Aminolevulinic Acid for Photodynamic Diagnosis of Malignant Glioma

NCT061604925-aminolevulinic Acid, Fluorescence-guided Resection, High-Grade Glioma (WHO III-IV)

Lee's Pharmaceutical Limited

Phase 3

Guangzhou, Zhengzhou

2025-04-14

Recruiting

Study on the Use of Lateral Decubitus Position in Left Breast Cancer Patients Undergoing Adjuvant Radiotherapy

NCT06902051Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Nanfang Hospital, Southern Medical University

Not applicable

Guangzhou

2025-04-14

Active, closed

Interventional Ablation for Early-stage Lung Cancer

NCT07005999Lung Cancer (NSCLC), Early Stage Lung Non-Small Cell Carcinoma

Guangzhou Institute of Respiratory Disease

Observational

656

Guangzhou

2025-04-12

Recruiting

A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

NCT06800196Solid Tumors With FGFR2 Alterations, Adult

KinoTeck Therapeutics Co., Ltd

Phase 1

151

Guangzhou

2025-04-10

Recruiting

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

NCT06992336Breast Cancer

DrugsBenmelstobart·Anlotinib·Capecitabine

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

430

Guangzhou

2025-04-10

Recruiting

Modulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer

NCT07066280Skin Microbiome, Breast Cancer, Radiation Dermatitis

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

326

Guangzhou

2025-04-10

Recruiting

SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases

NCT06794086Colorectal Cancer, Liver Metastases

DrugSintilimab

Jun Huang

Phase 3

Guangzhou

2025-04-10

Recruiting

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

NCT05066217Lennox Gastaut Syndrome

DrugClemizole HCl

Epygenix

Phase 3

260

Changsha, Shanghai, Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang

2025-04-09

Active, closed

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

NCT06822790Hypertriglyceridemia

DrugPlozasiran

Arrowhead Pharmaceuticals

Phase 3

710

Bengbu, Beijing, Guangzhou, Liuzhou, Xingtai, Luoyang, Changsha, Wuhan

2025-04-09

Recruiting

An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)

NCT06838845Ulcerative Colitis

AbbVie

Observational

Guangzhou, Zhengzhou

2025-04-09

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693Breast Cancer

DrugsCDK4/6i·Inavolisib·Letrozole

Hoffmann-La Roche

Phase 3

450

Xiangyang, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jiangmen

2025-04-09

Recruiting

Efficacy and Safety of Catheter abLation in patiEnts With seVere mitrAl regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial

NCT06883864Atrial Fibrillation (AF), Catheter Ablation, Atrial Functional Mitral Regurgitation

Beijing Anzhen Hospital

Not applicable

146

Hefei, Beijing, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan

2025-04-08

Recruiting

A Phase II Clinical Trial of Artificial Intelligence-assisted One-stop Radiotherapy for Breast Cancer After Breast-conserving Surgery

NCT06686459Breast Cancer Invasive

Sun Yat-sen University

Not applicable

860

Guangzhou

2025-04-06

Recruiting

Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma

NCT06912074Esophageal Squamous Cell Carcinoma (ESCC)

Sun Yat-sen University

Phase 2

134

Guangzhou

2025-04-05

Recruiting

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)

DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan

Gilead Sciences

Phase 3

695

Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin

2025-04-04

Recruiting

A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma

NCT06843889Locally Advanced Esophageal Squamous Cell Carcinoma

DrugToripalimab

Nanfang Hospital, Southern Medical University

Phase 2

Guangzhou

2025-04-03

Recruiting

Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df

NCT07348302Rhinitis, Rhinoconjunctivitis

Inmunotek S.L.

Phase 3

736

Beijing, Guangzhou, Zhongshan, Xiangya, Changzhou, Qingdao, Shanghai, Tongji

2025-04-02

Recruiting

A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy

NCT06839066Nasopharyngeal Carcinoma (NPC)

DrugsHLX43 3·HLX43 2·HLX43 1

Shanghai Henlius Biotech

Phase 2

Fuzhou, Dongguan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha

2025-04-02

Recruiting

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

NCT06868732Advanced Non-small Cell Lung Cancer

DrugsJSKN016·Ivonescimab·Tislelizumab·Docetaxel

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1

288

Guangzhou

2025-04-02

Recruiting

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

NCT06873945Alopecia Areata

DrugsLitfulo·Ritlecitinib

Pfizer

Phase 3

674

Beijing, Chongqing, Guangzhou, Changsha, Nanchang, Shanghai, Chengdu, Kunming

2025-04-01

Recruiting

Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma

NCT06825546Advanced Pancreatic Ductal Adenocarcinoma

DrugIcaritin

Sir Run Run Shaw Hospital

Phase 2

Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou, Wenzhou

2025-04-01

Recruiting

Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT

NCT06904183Hepatocellular Carcinoma Non-resectable

Second Affiliated Hospital of Guangzhou Medical University

Phase 2

320

Guangzhou

2025-04-01

Active, closed

Predictive Value of Preoperative Urine Culture for Postoperative Fever After FANS-RIRS When Surgery Proceeds Before Culture Results Are Available

NCT07514676Urolithiasis

The First Affiliated Hospital of Guangzhou Medical University

Observational

150

Guangzhou

2025-04-01

By invitation

Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)

NCT06966687Aortic Dissection, Aortic Dissection Aneurysm

Nanjing Medical University

Not applicable

200

Beijing, Guangzhou, Shanghai, Chengdu

2025-04-01

Not yet open

Liver Cancer Prognosis Investigation Study

NCT06623734Liver Neoplasms

Sun Yat-sen University

Observational

5,000

Guangzhou

2025-04-01

Recruiting

Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

NCT06904196Hepatocellular Carcinoma Non-resectable

DrugLenvatinib

Second Affiliated Hospital of Guangzhou Medical University

Phase 2

Guangzhou

2025-04-01

Not yet open

MSC-EVs in Acute/ Acute-on-Chronic Liver Failure After Liver Transplantation

NCT06825572Liver Failure, Mesenchymal Stem Cell, Extracellular Vesicles

Third Affiliated Hospital, Sun Yat-Sen University

Phase 1

Guangzhou

2025-04-01

Recruiting

Development of an AI-Agent for Urological Disease Diagnosis and Treatment

NCT07721935Urinary Stones, Prostate Cancer, Bladder Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Observational

2,000

Guangzhou, Shantou, Ganzhou

2025-04-01

Not yet open

An Intelligent Pressure and Temperature Control Ureteral Soft Scope System for Treating Stones With Infection.

NCT06841523Ureterolithiasis, Renal Calculi

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not applicable

288

Guangzhou

2025-04-01

By invitation

Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP

NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic

DrugRiliprubart

Sanofi

Phase 3

300

Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Wuhan

2025-04-01

Not yet open

Methylprednisolone With Endovascular Thrombectomy for Large Ischemic Stroke

NCT06870448Acute Ischemic Stroke

DrugMethylprednisolone

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

1,614

Guangzhou

2025-04

Not yet open

Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.

NCT06885840Non-Small Cell Lung Cancer

DrugMCLA-129

Betta Pharmaceuticals Co., Ltd.

Phase 2

100

Hefei, Lanzhou, Dongguan, Foshan, Guangzhou, Baoding, Harbin, Zhengzhou

2025-03-31

Active, closed

Anxiety in Cataract Patients Using Preoperative Music Therapy

NCT07296731Cataract, Music Therapy

Guangzhou First People's Hospital

Not applicable

Guangzhou

2025-03-31

Active, closed

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

NCT06921486Obesity and Overweight

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

Phase 2/3

1,003

Beijing, Changzhou, Chengdu, Guangzhou, Guangzhusi, Guizhou, Hangzhou, Harbin

2025-03-31

Recruiting

To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A

NCT06833983Hemophilia A

DrugGS1191-0445

Gritgen Therapeutics Co., Ltd.

Phase 3

Hefei, Beijing, Lanzhou, Guangzhou, Tangshan, Zhengzhou, Wuhan, Changsha

2025-03-31

Recruiting

Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)

NCT06923345Rectal Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2

Guangzhou

2025-03-31

By invitation

TAF in Early/Middle Pregnancy With CHB

NCT07668934Hepatitis B Infection, Pregnant Women, Early Pregnancy

The Third Affiliated Hospital of Guangzhou Medical University

Phase 4

816

Guangzhou

2025-03-31

Not yet open

Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC

NCT06900478Hepatocarcinoma

DrugTACE

Hua Li

Phase 2

Guangzhou

2025-03-30

Recruiting

Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

NCT06868836Non-squamous Non-small Cell Lung Cancer

DrugsJS212·JS207·Pemetrexed·Cisplatin

Shanghai Junshi Bioscience Co., Ltd.

Phase 2

Guangzhou

2025-03-30

Active, closed

QL1706 Plus Neoadjuvant Chemotherapy Followed by Type I Hysterectomy for Locally Advanced Cervical Cancer

NCT07205497Neoadjuvant Immunotherapy, Locally Advanced Cervical Cancer

DrugLenvatinib

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Guangzhou

2025-03-28

Recruiting

Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

NCT07152041Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic

DrugsOlverembatinib·Blinatumomab·Daunorubicin·Cytarabine

Institute of Hematology & Blood Diseases Hospital, China

Phase 3

150

Hefei, Chongqing, Fuzhou, Guangzhou, Guiyang, Wuhan, Changsha, Nanjin

2025-03-28

Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112Endometrial Cancer

DrugsRilvegostomig·Taxotere·Paraplatin·Trastuzumab deruxtecan

AstraZeneca

Phase 3

600

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou

2025-03-27

Recruiting

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

NCT06795022Hepatocellular Carcinoma

AstraZeneca

Phase 1/2

304

Chengdu, Guangzhou, Harbin, Shanghai

2025-03-27

Recruiting

A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation

NCT06898385Pancreatic Cancer

DrugsEndoxan·Fludara·Fludarabine·Cyclophosphamide

Sun Yat-sen University

Phase 1

Guangzhou

2025-03-27

Recruiting

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

NCT06890598Carcinoma, Non-Small-Cell Lung

DrugsOlomorasib·Durvalumab·Pembrolizumab

Eli Lilly and Company

Phase 3

700

Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Foshan, Guangzhou

2025-03-27

Recruiting

Tubeless VATS for Mediastinal Neoplasm

NCT07065604Mediastinal Neoplasm, VATS, Tubeless, Non-intubated Anesthesia

Shuben Li

Not applicable

132

Guangzhou

2025-03-26

Recruiting

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT06932263Asthma

DrugTozorakimab

AstraZeneca

Phase 2

540

Baotou, Changchun, Chengdu, Chongqing, Guangzhou, Haikou, Hefei, Hohhot

2025-03-26

Active, closed

Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients

NCT06922045Hemophilia

Jiangsu BioJeTay Biotechnology Co., Ltd.

Phase 3

Hefei, Lanzhou, Guangzhou, Shenzhen, Nanning, Tangshan, Harbin, Zhengzhou

2025-03-26

Recruiting

This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.

NCT06756451Hematologic Malignancies

Nanjing RegeneCore Biotech Co., Ltd.

Phase 1

Hefei, Guangzhou, Shenzhen, Guilin, Nanning, Baoding, Tangshan, Zhengzhou

2025-03-25

Recruiting

Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma

NCT06837922Asthma

Shanghai Mabgeek Biotech.Co.Ltd

Phase 3

504

Guangzhou

2025-03-25

Recruiting

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer

NCT07056777Gastrointestinal Cancer

DrugsDR30206·Calcium folinate·Irinotecan·Adrucil

Zhejiang Doer Biologics Co., Ltd.

Phase 1/2

186

Guangzhou

2025-03-25

Not yet open

Reconstruction of Cervical Lymphatic System During Head and Neck Squamous Cell Carcinoma Surgery

NCT06815705Head and Neck Squamous Cell Carcinoma, Lymphedema, Secondary, Neck Lymph Dissection, Vascularized Lymph Node Transplantation

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not applicable

Guangzhou

2025-03-20

Recruiting

Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

NCT06842199Plaque Psoriasis Patients

DrugICP-488

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 3

383

Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Liuzhou, Guiyang

2025-03-20

Recruiting

Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma

NCT07336979Resectable Mucosal Melanoma

Sun Yat-sen University

Phase 2

Guangzhou

2025-03-20

Recruiting

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

NCT06819007Ovarian Cancer

DrugsTrastuzumab deruxtecan·Bevacizumab

Daiichi Sankyo

Phase 3

582

Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou

2025-03-19

Recruiting

A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors

NCT06826313Solid Tumors

DrugVRT106

Guangzhou Virotech Pharmaceutical Co., Ltd.

Phase 1

Guangzhou

2025-03-19

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305Chronic Obstructive Pulmonary Disease (COPD)

DrugTezepelumab

AstraZeneca

Phase 3

990

Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou

2025-03-18

Active, closed

Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia

NCT06686485Concomitant Procedures, Atrial Fibrillation, PFA, LAAC

Boston Scientific Corporation

Observational

433

Suzhou, Beijing, Chengdu, Guangzhou, Guiyang, Hangzhou, Jinan, Kunming

2025-03-18

Recruiting

A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer

NCT06758544Pancreatic Cancer

DrugVRT106

Guangdong Provincial People's Hospital

Phase 1/2

Guangzhou

2025-03-17

Recruiting

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819878Moderately to Severely Active Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 3

600

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou

2025-03-17

Recruiting

Steerable vs Conventional FANS for <2cm Lower Pole Stone Treatment: SCULPT Trial

NCT06898216Kidney Stones

The First Affiliated Hospital of Guangzhou Medical University

Not applicable

400

Guangzhou

2025-03-16

Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

NCT06841354Triple Negative Breast Neoplasms

DrugsAbraxane·Paraplatin·Sacituzumab tirumotecan·Taxol

Merck Sharp & Dohme LLC

Phase 3

1,000

Bengbu, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Wuhan, Xiangyang

2025-03-16

Active, closed

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

NCT06795048Neovascular Age-related Macular Degeneration (nAMD)

DrugsVabysmo·Faricimab

Hoffmann-La Roche

Phase 4

274

Beijing, Chengdu, Guangzhou, Shanghai, Wuhan

2025-03-14

Recruiting

Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma

NCT06587802Adrenocortical Carcinoma

Sun Yat-sen University

Phase 2

Guangzhou

2025-03-14

Active, closed

A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

NCT06883630Non-Small Cell Lung Cancer

DrugRC148

RemeGen Co., Ltd.

Phase 1

121

Beijing, Foshan, Guangzhou, Jiangmen, Gulin, Nanning, Harbin, Hanyang

2025-03-13

Recruiting

A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced

NCT06798207Gynecological Tumors

DrugTQB2102

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 2

170

Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Meizhou, Qingyuan, Nanning

2025-03-13

Recruiting

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

NCT06869551Juvenile Psoriatic Arthritis

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

Beijing, Chongqing, Guangzhou, Nanjing, Changchun, Hangzhou, Shanghai

2025-03-13

Active, closed

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06764485Metastatic Castration-resistant Prostate Cancer

DrugsAbiraterone·Enzalutamide·Docetaxel

Celgene

Phase 3

960

Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Huizhou, Changzhou, Nanjing

2025-03-13

Active, closed

Safety and Preliminary Antitumor Activity of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma

NCT07885306Malignant Pleural Mesothelioma, Advanced

DrugIvonescimab

Ruijin Hospital

Phase 1

Guangzhou, Shanghai, Chengdu

2025-03-12

Recruiting

Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma

NCT06854445Diffuse Large Cell B-lymphoma

DrugsTQB2825·Oxaliplatin·Gemcitabine

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Phase 2

Wuhu, Xiamen, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Zhengzhou

2025-03-12

Recruiting

Newly-diagnosed Pediatric T-cell ALL Protocol

NCT06855810Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

DrugsAsparaginase·Homoharringtonine·Dasatinib·Daunorubicin

Institute of Hematology & Blood Diseases Hospital, China

Phase 2/3

610

Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha

2025-03-11

Recruiting

Proton Therapy for Recurrent Nasopharyngeal Carcinoma

NCT07412314Recurrent Nasopharyngeal Carcinoma

Guangzhou Concord Cancer Center

Not applicable

Guangzhou, Guanzhou

2025-03-10

Active, closed

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

NCT06671496Psoriatic Arthritis

DrugZasocitinib

Takeda

Phase 3

601

Bengbu, Beijing, Xiamen, Guangzhou, Shenzhen, Luoyang, Wuhan, Zhuzhou

2025-03-10

Not yet open

Clinical Features and Current Treatment of Primary Headache

NCT06883955Primary Headache

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Observational

2,000

Guangzhou

2025-03-08

Recruiting

A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors（G-MAP 101）

NCT06796699Advanced Solid Tumors With MTAP Deletion

Suzhou Genhouse Bio Co., Ltd.

Phase 1

200

Beijing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning, Guiyang, Zhengzhou

2025-03-07

Active, closed

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR

DrugALXN2030

Alexion Pharmaceuticals, Inc.

Phase 2

Changsha, Guangzhou, Nanning, Shanghai, Wuhan, Xi'an

2025-03-07

Recruiting

A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06716138Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration

Avistone Biotechnology Co., Ltd.

Phase 1

Fuzhou, Guangzhou, Shanghai, Chengdu

2025-03-06

Recruiting

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 3

300

Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Xuzhou

2025-03-05

Recruiting

Construction of a Multi-dimensional Risk Assessment System: a Clinical Study of Polycystic Ovary Syndrome Complicated With Thrombophilia

NCT07571096Polycystic Ovary Syndrome (PCOS), Thrombophilia

Guangdong Women and Children Hospital

Observational

100

Guangzhou

2025-03-04

Recruiting

Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

NCT06882057Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)

DrugsAsparaginase·Blinatumomab·Daunorubicin·Cytarabine

Institute of Hematology & Blood Diseases Hospital, China

Phase 2/3

3,000

Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha

2025-03-03

Not yet open

Deep Sedation in Catheter Ablation of Atrial Fibrillation

NCT06836999Atrial Fibrillation, Atrial Fibrillation, Paroxysmal or Persistent, Deep Sedations, Conscious Sedation

The First Affiliated Hospital of Dalian Medical University

Not applicable

1,334

Hefei, Guangzhou, Nanjing, Suzhou, Nanchang, Dalian, Qingdao, Shanghai

2025-03-03

Not yet open

Study on the Correlation and Consistency of Measuring Biologic Drug Plasma Concentrations Based on Different Detection Methods

NCT06849739Inflammatory Bowel Diseases

Nanfang Hospital, Southern Medical University

Observational

Guangzhou

2025-03-02

Recruiting

Improve the Strategies of Endoscopic and Interventional Treatment of Gastroesophageal Hemorrhage in Portal Hypertension

NCT06970509Esophageal Varices, Portal Hypertension

Shanghai Zhongshan Hospital

Observational

1,450

Guangzhou, Nanchang, Shenyang, Jinan, Shanghai

2025-03-01

Recruiting

Multimodal AI-Guided Recovery Management After Lung Cancer Surgery

NCT07588737Postoperative Care, Rehabilitation, Artificial Intelligence (Al), Randomized Controlled Trial (RCT)

The First Affiliated Hospital of Guangzhou Medical University

Not applicable

868

Guangzhou

2025-03-01

Recruiting

The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.

NCT06851299Metastatic Triple-negative Breast Cancer

DrugTROP2 ADC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Guangzhou

2025-03-01

Not yet open

Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

NCT06871527Gastric (Stomach) Cancer, Gastric Adenocarcinoma, Fruquintinib, PD-1 Inhibitor

DrugsFruquintinib·Folfox·Tislelizumab

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 1/2

Guangzhou

2025-03-01

Not yet open

CAP-TEER: CerebrAl Protection During Transcatheter Edge-to-edge Repair

NCT06814210Mitral Regurgitation, Functional Mitral Regurgitation, Degenerative Mitral Valve Regurgitation

Xiao-dong Zhuang

Not applicable

120

Guangzhou

2025-03-01

Recruiting

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil

AstraZeneca

Phase 3

840

Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou

2025-03-01

By invitation

Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study

NCT06843681Breast Carcinoma in Situ

DrugTrastuzumab

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2

Guangzhou

2025-03-01

Recruiting

Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer

NCT06854250Metastatic Prostate Cancer

DrugCyclophosphamide

Sun Yat-sen University

Phase 2

104

Guangzhou

2025-03-01

Not yet open

Guideline-diRected MAnagement for Chronic Kidney Disease: EValuation of an Education Progamme in a National Cluster Randomized Controlled Trial

NCT06825676Renal Insufficiency, Chronic, Cardiovascular Diseases (CVD)

Guangdong Provincial People's Hospital

Not applicable

1,800

Guangzhou

2025-03

Not yet open

Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)

NCT06859931Systemic Lupus Erythematosus

DrugTQB3702

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

120

Bengbu, Hefei, Beijing, Lanzhou, Guangzhou, Shenzhen, Nanning, Langfang

2025-03

Not yet open

AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)

NCT06860789Chemotherapy-induced Peripheral Neuropathy (CIPN)

Akeso

Phase 1

Guangzhou, Shanghai

2025-02-28

Not yet open

The Effects of Glasses-Free 3D Training on Visual and Cognitive Function in Presbyopic Individuals

NCT06853691Presbyopia

Zhongshan Ophthalmic Center, Sun Yat-sen University

Not applicable

Guangzhou

2025-02-27

Recruiting

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

NCT06780670Prostate Cancer

DrugAAA817

Novartis Pharmaceuticals

Phase 2/3

443

Fuzhou, Wuhan, Nanjing, Shenyang, Xian, Chengdu, Beijing, Guangzhou

2025-02-27

Active, closed

Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1)

NCT06892301Type 1 Primary Hyperoxaluria

DrugYOLT-203

Guangzhou Women and Children's Medical Center

Early Phase 1

Guangzhou

2025-02-27

Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

NCT06767514Non-Small Cell Lung Cancer

DrugsIvonescimab·Pembrolizumab

Summit Therapeutics

Phase 3

780

Fuyang, Beijing, Fuzhou, Guangzhou, Nanning, Guiyang, Haikou, Harbin

2025-02-27

Recruiting

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China

NCT06846996HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Observational

260

Beijing, Changchun, Changzhi, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei

2025-02-27

Recruiting

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06722235Immune Thrombocytopenic Purpura (ITP)

DrugMezagitamab

Takeda

Phase 3

171

Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang

2025-02-27

Recruiting

A Study of HS-20110 in Participants With Advanced Solid Tumors

NCT06892379Solid Tumors

DrugHS-20110

Hansoh BioMedical R&D Company

Phase 1

475

Guangzhou

2025-02-26

Recruiting

SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

NCT06873659Solid Tumor, Gastric Cancer, Liver Cancer

Qurgen Inc.

Phase 1

Beijing, Lanzhou, Guangzhou, Nanjing, Xi'an, Jinan, Shanghai, Hangzhou

2025-02-26

Recruiting

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)

NextCure, Inc.

Phase 1

738

Beijing, Shenyang, Shijiazhuang, Guangzhou, Changsha, Jinan, Jining, Shanghai

2025-02-26

Active, closed

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

NCT06745323Small Cell Lung Cancer (SCLC)

DrugTarlatamab

Amgen

Phase 2

252

Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Taiyuan, Chengdu, Tianjin

2025-02-26

Recruiting

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

NCT06741644Advanced Solid Tumors

DrugsLeucovorin·Irinotecan·Adrucil·Etoposide

CStone Pharmaceuticals

Phase 1/2

800

Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin

2025-02-24

Active, closed

A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy

NCT06797297Melanoma

DrugsLenvatinib·Pembrolizumab

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

203

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin

2025-02-24

Active, closed

Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma.

NCT06854510Nasopharyngeal Cancinoma (NPC)

Sun Yat-sen University

Phase 2/3

196

Guangzhou

2025-02-21

Recruiting

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

NCT06839105Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor

DrugsAWT020·Taxol·Pemetrexed·Capecitabine

Shanghai Junshi Bioscience Co., Ltd.

Phase 1

214

Fuzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changsha, Nanchang, Changchun

2025-02-21

Recruiting

Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer

NCT06889688Breast Cancer Stage IV, Triple -Negative Breast Cancer

DrugsEribulin·Apatinib·Camrelizumab

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3

246

Guangzhou, Guiyang, Wuhan, Yichang, Changsha, Yongzhou, Shanghai

2025-02-21

Active, closed

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

NCT06878404Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

552

Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Linyi

2025-02-21

Recruiting

Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma

NCT06793956Extranodal Natural Killer/T Cell Lymphoma

Sun Yat-sen University

Phase 1

Guangzhou

2025-02-21

Recruiting

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)

NCT06809764Non-small Cell Lung Cancer

Daiichi Sankyo

Observational

150

Beijing, Changsha, Fuzhou, Guangdong, Guangzhou, Hangzhou, Hebei, Hefei

2025-02-21

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=3

Query this register directly

GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,345 of those studies with a site in Guangzhou.

How many clinical trials are recruiting in Guangzhou?

1,977 of the 3,345 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 479 have not yet opened recruitment, 820 are active but closed to new participants, and 69 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.